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Studies on chemical… 
Synopsis                                                                                                                                1 
 The research work incorporated in the thesis with the title “STUDIES ON 
CHEMICAL ENTITIES OF THERAPEUTIC INTEREST” has been described as 
under. 
 
PART-A : STUDIES ON INDOLE-2-CARBOXYLIC ACID DERIVATIVES 
PART-B : STUDIES ON IMIDAZO[1,2-a]PYRIDINE DERIVATIVES 
PART-C : STUDIES ON THIOPHENE DERIVATIVES 
 
PART-A : STUDIES ON INDOLE-2-CARBOXYLIC ACID DERIVATIVES 
 Nowadays, the entire pharmaceutical industry is faced with the challenge of 
increasing productivity and innovation. The major hurdles are the increasing costs of 
research and development and a simultaneous stagnating number of new chemical entities 
(NCEs). So the primary goal of the our research work is to find and develop new 
chemical entities (NCEs) 
 Indole nucleus possesses remarkable pharmaceutical importance and biological 
activities, some of their derivatives occur as natural products, amino acid, hormones etc. 
In animals serotonin is a very important neurotransmitter in the central nervous system 
and also plays a vital role in the cardiovascular and gastrointestinal system. Many indole 
derivatives are used as pharmaceuticals and highly selective medicines which are in 
current use. In view of our on going interest in the synthesis of some new potentially 
bioactive indole derivatives have been described as under. 
 
PART-I: STUDIES ON INDOLE-3-YL-GLYOXYLAMIDE DERIVATIVES 
The synthesis of compounds incorporating indole-3-yl-glyoxylamide has been 
attracted widespread attention due to their diverse pharmacological properties like 
anticancer, anti-inflammatory, antibiotic, antifungal, herbicidal, antitubercular etc. To 
approach this goal syntheses of some indole-3-yl-glyoxylamides have been undertaken, 
which have been described as under. 
 
SECTION-I: Synthesis and biological evaluation of 3-[N,N-Dialkylamine(oxo) 
acetyl]-1-propyl-1H-indole-2-carboxylic acids. 
 
Studies on chemical… 







R = Seco. amine 
                                                                 Type (I) 
 Indole-3-yl-glyoxylamide derivatives of Type (I) have been synthesized by the 
condensation of 1-propyl-1H-indole-2-carboxylic acid  with oxalyl chloride and different 
secondary amine in the presence of DCM. 
 
PART-II: STUDIES ON IMIDAZOLONE DERIVATIVES 
 The discovery of imidazolone as potent biologically active agent has led to the 
exploration of large number of structural variants, containing imidazolone moiety as an 
invariable ingredient. Its derivative have shown various biologically activities such as 
anathematic, antimicrobial, antihistamine, anti-inflammatory, antibacterial etc. in order to 
develop therapeutically important compounds, it was consider of interest to synthesize 
some imidazolones shown as under. 
 












R= Aryl  
Type (II)   
 The synthesis of imidazolones of Type (II) have been under taken by the reaction 
of 1H-indole-2-carbohydrazide with substituted azalactone which in turn have been 
prepared by well known Erlenmeyer azalactone synthesis. 
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PART-III: STUDIES ON OXADIAZOLE DERIVATIVES 
1,3,4-Oxadiazoles are associated with broad spectrum of pharmacological activity 
like anesthetic, hypnotic, antibacterial, hypoglycemic and antifungal. These valid 
observations promoted us to synthesize 1,3,4-oxadiazole derivatives with better 
therapeutic value which have been described as under. 
 











Type (III)  
The oxadiazole derivatives of Type (III) have been synthesized by the 
condensation of 1-propyl-1H-indole-2-carbohydrazide with various aromatic acids in the 
presence of POCl3. 
 
PART-B : STUDIES ON IMIDAZO[1,2-a]PYRIDINE DERIVATIVES 
 Heterocyclic compounds bearing imidazo[1,2-a]pyridine ring system are endowed 
with variety of biological activities. Our strategy is based on to develop a new bioactive 
entity especially with pharmacological activities bearing heterocyclic ring system. 
Literature survey reveals that nitrogen containing heterocyclic compounds like 
imidazo[1,2-a]pyridines have received considerable attention in medicinal science due to 
their biological and pharmacological activities like anti-inflammatory, antitumor, calcium 
channel blocker, hypnotic, sedative, antimicrobial, antitubercular, CNS depressant, 
antithyroid and many other therapeutic activities. 
 These valid observations led us to design and synthesize some heterocycles like 
glyoxylamide, mannich bases, bis-imidazo[1,2-a]pyridine etc., bearing imidazo[1,2-
a]pyridine nucleus, which have been described as under. 
 
PART-I: STUDIES ON IMIDAZO[1,2-a]PYRIDINE-3-YL-GLYOXYLAMIDE     
      DERIVATIVES 
Studies on chemical… 
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Imidazo[1,2-a]pyridine-3-yl-glyoxylamide derivatives have been found to be 
potent drug in pharmaceutical and possess a wide range of pharmacological activities 
such as anticancer, anticonvulsant, hypnotic, antithyroid, anti-inflammatory etc. It 
appeared of interest to design and synthesize imidazo[1,2-a]pyridine-3-yl-glyoxylamide 
derivative, which have been describe as under. 
 











R= Seco. amine  
Type (IV)   
 Imidazo[1,2-a]pyridine-3-yl-glyoxylamide derivatives of Type (IV) have been 
synthesized by the condensation of 2-(4-fluorophenyl)-6-methylimidazo[1,2-a]pyridine 
with oxalyl chloride and different secondary amine in the presence of DCM. 
 
PART-II: STUDIES ON MANNICH BASE DERIVATIVES   
Compound containing bridge N-atom exhibit pronounced pharmacological 
activities. Mannich base derivatives with bridge N-atom have been found to potent drug 
in medicine science and possess a wide range of therapeutic activities like 
antihypertensive, antidepressant, anticholestemic, antifungal etc. by consideration this 
valid observations, to approach this goal we have synthesize some new mannich bases, 
which have been shown as under.    
 








R= Seco. amine  
Type (V)   
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 Mannich bases of Type (V) have been synthesized by the condensation of 2-(4-
fluorophenyl)-6-methylimidazo[1,2-a]pyridine with different secondary amines and 
formaldehydes in the presence of acid catalyst. 
  
PART-III: STUDIES ON BIS-IMIDAZO[1,2-a]PYRIDIN DERIVATIVES 
Bis imidazo[1,2-a]pyridine derivatives are important intermediates in organic 
synthesis, especially in the synthesis of biologically active and medicinally useful agents. 
For instance, they are widely used in the synthesis of cyclin-dependent kinases (CDK) 
inhibitors, sleep inducers, anticonvulsant agents, antiviral agents etc. The synthesis of 
some new potentially bioactive bis imidazo[1,2-a]pyridine derivatives have been 
undertaken. 
 















Type (VI)  
Bis imidazo[1,2-a]pyridine derivatives of Type (VI) have been synthesized by the 
condensation of the 2-(4-fluorophenyl)-6-methylimidazo[1,2-a]pyridine with different 
aryl aldehyde  and sodium acetate.  
 
PART-C : STUDIES ON THIOPHENE DERIVATIVES 
Thiophen nucleus represents important building blocks in both natural and 
synthetic bioactive compounds, which have been shown to possess diverse therapeutic 
activities. Our works are paying attention on introduction of chemical multiplicity in the 
molecular frame work, in order to synthesizing active molecules of widely different 
composition. Literature assessment reveals that sulfur containing heterocyclic compounds 
has been shown to have a broad range of important biological and pharmacological 
activities such as anti-HIV, antitubercular, antimicrobial, anticonvulsant, anticancer, 
Studies on chemical… 
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antiviral etc. Considering the increasing importance of thiophene nucleus, we have 
undertaken the synthesis of some new pyrazoline and pyrimidine derivatives bearing 
thiophene nucleus, which have been described as under. 
 
PART-I: STUDIES ON PYRAZOLINE DERIVATIVES 
In the present chapter, the efforts have been made for the synthesis of pyrazoline 
derivatives. Substituted pyrazoline derivatives have drawn considerable attention of the 
chemist due to their good pharmacological activities like antibacterial, anticonvulsant, 
analgesic etc. with a view to getting better therapeutic agent and to evaluate 
pharmacological profile, different types of pyrazoline derivatives have been prepared 
which have been described as under.  
 










R = thiophene/aryl  
 R1 = aryl/thiophene 
 Type (VII)   
Pyrazoline derivatives of Type (VII) have been synthesized by the 
cyclocondensation of the 1H-indole-2-carbohydrazide and different substituted chalcones 
under acidic condition. 
 
PART-II: STUDIES ON PYRIMIDINE DERIVATIVES 
The chemistry of pyrimidine and its derivatives has been studied for over a 
century due to their diverse biological activities. Due to formal isoelectronic relationship 
with purines, the pyrido[2,3-d]pyrimidine ring system is of special biological interest. It 
has numerous pharmacological and medicinal applications viz, antitumour, 
immunodilator, tuberculosis, antiallergic and radioprotective. 
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R = thiophen/aryl 
 R1 = aryl/thiophen 
Type (VIII)   
The synthesis of pyrido[2,3-d]pyrimidines of Type (VIII) was achieved by acid 
catalysed cyclocondensation of 2-amino-6-aryl/thiophene-4-(thiophene/aryl-2-
yl)pyridine-3-carbonitrile with glacial acetic acid. 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR and 13C NMR spectroscopy and further 
supported by mass spectroscopy. Purity of all the compounds have been checked on thin 
layer chromatographic plate and HPLC technique. 
All the compounds have been evaluated for their antibacterial activity towards 
Gram +ve and Gram -ve bacterial strains and antifungal activity towards Aspergillus 
niger at a concentration 40 µg/ml. The biological activities of the synthesized compounds 











Part – A 
Introduction 
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INTRODUCTION 
Indole (2,3-benzopyrrole, ketole, 1-benzazole; C8H7N) is an aromatic heterocyclic 
organic compound. It has a bicyclic structure, consisting of a six-membered benzene ring 
fused to a five-membered nitrogen-containing pyrrole ring. The participation of the 
nitrogen lone pair electron in the aromatic ring means that indole is not a base, and it does 
not behave like a simple amine.  
Indole is a solid at room temperature. It can be produced by bacteria as a 
degradation product of the amino acid tryptophan. It occurs naturally in human faces and 
has an intense facial odor. At very low concentrations, however, it has a flowery smell, 
and is a constituent of many flower scents (such as orange blossoms) and perfumes. It 












Indole compounds include the plant hormone Auxin (indolyl-3-acetic acid), the 
anti-inflammatory drug indomethacin, the betablocker pindolol, and the naturally 
occurring hallucinogen dimethyltryptamine. 
The name indole is a portmanteau of the words indigo and oleum, since indole 
was first isolated by treatment of the indigo dye with oleum. Indole chemistry began to 
develop with the study of the dye indigo. Indigo can be converted to isatin and then to 
oxindole. Then, in 1866, Adolf von Baeyer reduced oxindole to indole using zinc dust.1 In 
1869, he proposed a formula for indole.2  
Certain indole derivatives were important dyestuffs until the end of the 19th 
century. In the 1930, interest in indole intensified when it became known that the indole 
nucleus is present in many important alkaloids, as well is in tryptophan and auxins, and it 
remains an active area of research today.3 
The indole skeleton is one of the most attractive frameworks with a wide range of 
biological and pharmacological activities.4 This physiologically important nucleus is 
abundantly found in therapeutic agents5,6 as well as in natural products. Many researchers 
have described synthesis of indole and its derivatives along with its applications in 
literature.7 
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SYNTHETIC ASPECT 
Various methods for the preparation of indole derivatives have been cited in 
literature, some of them are as under. 
1. B. George8 has reported one-pot microwave assisted synthesis of indole from 












2. N. Sakai et al.9 have cyclized 2-ethynylanilines by indium as catalyst and 
produced various indole derivatives in good yields for substrates having an alkyl 









5 mol -% in Br3










3. Rhodium (II) perfluorobutyrate-mediated decomposition of vinyl azides 
allows rapid access to a variety of complexes of indole was prepared by B. 


















4. Y. Du and coworkers11 have been synthesized various N-arylated and N-alkylated 
indoles and pyrrole-fused aromatic compounds by a phenyliodine 



















CH2Cl2, RT, 30 min
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5. Microwave-assisted synthesis of indole derivatives in water via 
cycloisomerization of 2-alkynylanilines and alkynylpyridinamines promoted by A. 

















6. Synthesis of 2-substituted indoles via palladium-catalyzed domino Heck reaction 












7. D. K. Whelligan and coworkers15 have synthesized two-step aza- and diazaindoles 











8. One-pot synthesis of indole derivatives from nitroarenes under hydrogenation 












9. A mild preparation of substituted indole from simple aromatic precursors using 
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12. G. A. Kraus and coworkers20 have synthesized indole derivatives under 















13. Gold(III)-catalyzed indole derivatives from 2-alkynylanilines in EtOH annulations 

















14. Copper(II)-catalyzed cyclization of 2-ethynylaniline derivatives to indoles can be 
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15. A. Dobbs et al.23 have synthesized indole derivatives from ortho-
























16. One-pot synthesis of indoles by a palladium-catalyzed annulation of ortho-
iodoanilines and aldehydes under mild ligandless conditions in DMF was reported 




















DABCO, DMF, 85 oC
 
 
17. Suzuki-Miyaura coupling of ortho-gem-dihalovinylanilines with boronic acids, of 
a Pd(OAc)2 catalyst in the presence of K3PO4·H2O was doccumented by Y. Q. 






































19. Lewis acids catalyzed cyclization of methyl phenyldiazoacetates was reported by 
L. Zhou et al.27  
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 The reaction of phenyl hydrazine with an aldehyde or ketone initially forms 
phenylhydrazone which isomerizes to the respective enamine. After protonation, a cyclic 
sigmatropic rearrangement occurs producing an imine. The resulting imine forms a cyclic 
aminoacetal, which under acid catalysis eliminates NH3, resulting in the energetically 




































The indole ring system represents a privileged structure in drug discovery. The 
number of bioactive compounds containing this ring system is so vast that the complete 
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14. Anti HIV44 




B. Pelcman et al.48 have synthesized marine sponge pigment fascaplysin (2) from 







M. C. Pirrung et al.49 have synthesized indolylquinones (3) and checked their 
activity on the human insulin receptor by demethylasterriquinone B1 (DAQ B1) and its 
consequent oral insulin mimetic activity tested in mice by B. Zhang and coworkers.50 
DAQ B1 was also subsequently shown to activate the TrkA nerve growth factor receptor 











Activities of asterriquinones (4) against HIV protease and HIV reverse 
transcriptase have been disclosed by A. Fredenhagen et al.52 and K. Ono et al.53 and also 
activity against serine proteases given by U. Mocek et al.54 
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R = H, CH3
(4)  
 
S. Pasquini et al.55 prepared library of 1,5-disubstituted-3-indole-N-
alkylacetamides as CB2 receptor ligands. Some representatives of CB2 agonists are 
compounds AM1241, GW405833, JWH-015 and AM630 possess an indole structure 





















AM1241 GW405833 JWH-015 AM630
 













R1 = OH, H, F  R2 = H, OCH3




P. Diana et al.59 have synthesized 3,5-bis(3’-indolyl)pyrazoles (6) by cyclization 
of diketones and hydrazine monohydrate and evaluated their antitumor properties. The 
interest in this class of compounds has been stimulated by both their unique chemical 
structure and the wide range of biological properties including antiviral, antimicrobial, 
and antitumor activity was given by V. M. Dembitsky et al.60 
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R = H, P(O)(OH)2
(7)  
 
E. J. Glamkowski et al.62 have synthesized 3-(4-acylaminopiperazin-1-













M. Banerjee et al.63 have synthesized indole derivatives, such as HIV-1 
nonnucleoside reverse transcriptase inhibitor. D. C. Cole et al.64 have tested 5-HT 
receptor agonists or antagonists. Q. Shi et al.65 and H. D. H. Showalter et al.66 have 
synthesized and tested peroxisome proliferator-activated receptor (PPAR) agonists and 
protein tyrosine kinase inhibitors. G. Primofiore and coworkers67 and K. L. Lee et 
al.68 have prepared and tested benzodiazepine receptor (BzR) ligands. Human cytosolic 
phospholipase A2R inhibitor and blood coagulation factor Xa inhibitor have also been 
presented by H. Matter et al.69 
J. Holenz et al.70 prepared medicinal chemistry driven approaches toward novel 
and selective serotonin 5-HT6 receptor ligands (9). 
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Preparation and antibacterial activities of indole containg compounds reported by 
Y. Yasuo et al.71 T. Bhawana et al.72 have synthesized and tested antimicrobial activity 
of indole derivatives. Synthesis and biological screening of some new indole 
derivatives doccumented by D. S. Mehta et al.73 and G. S. Gadaginamath et al.74 Potent 
antimicrobial activity of indole derivatives against methicillin-resistant Staphylococcus 
aureus investigated by  R. A. Al-Qawasmeh et al.75 Regioselective synthesis and 
biological evaluation of bis(indolyl)methane derivatives as anti-infective agents given 
by M. Damodiran et al.76 
Discovery of indole inhibitor of cytosolis phospholipase A2α reported by K. L. 
Lee et al.77 Y. Kawashima et al.78 have studied structure activity of indole derivatives 
with analgesic and anti-inflammatory activities. Synthesis and anti-inflammatory 
activity of heterocyclic indole derivatives reported by R. Preeti et al.79 Amido indole 
derivatives used in cannabinoid receptor modulators discovered by H. John et al.80 
M. G. Bursavich et al.81 have synthesized indole derivatives and tested for PI3 
kinase-α and the mammalian target. Synthesis and evaluation of indole derivatives as 
antagonists of Wnt/β-catenin, signaling and CLL cell survival reported by J. Guangyi 
et al.82 D. A. James and coworkers83 synthesized conjugated indole-imidazole 
derivatives, displaying cytotoxicity against multidrug resistant cancer cell lines. C. 
Girolamo et al.84 have synthesized derivatives of the new ring system indole with 
potent antitumor and antimicrobial activity. B. Emile et al.85 have synthesized 
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Thus the important role displayed by indole and its derivatives for various 
therapeutic and biological activities prompted us to synthesize some Glyoxylamide, 
Imidazolone and Oxadiazole derivatives bearing indole moiety in order to achieve 
compounds having better therapeutic activities described as in the following parts. 
 
 
STUDIES ON INDOLE-2-CARBOXYLIC ACID DERIVATIVES 
 
PART-I: STUDIES ON INDOLE-3-YL-GLYOXYLAMIDE DERIVATIVES  
PART-II: STUDIES ON IMIDAZOLONE DERIVATIVES 
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INTRODUCTION     
Indole-3-yl-glyoxylamide derivatives are potent biologically active agent has led 
to the exploration of large number of structural variants, containing indole-2-carboxylic 
moiety as an invariable ingredient so the synthesis of these compounds has become an 
important target in current years. The diversity, efficiency and rapid access to small and 
highly functionalized organic molecules makes this approach of central current interest in 











A new class of indole-3-yl-glyoxylamide derivatives is high affinity agonists at 
the benzodiazepine binding site receptors. It has proved a rich source of clinically 
effective drugs, particularly anxiolytics, hypnotics and anticonvulsants. 
 
SYNTHETIC ASPECT 
Various methods for the preparation of 3-oxoacetamide-1H-indole derivatives and 
alkylation of indole have been cited in literature, some of the methods are as under. 
 
ALKYLATION  
1. K. T. Potts et al.3 have synthesized 1-methylindole from indole, CH3I and NaNH2 







2. R. S. Davidson et al.4 have reported N-alkylation of indole using phase transfer 
catalyst with ultrasound. 
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3. Potassium carbonate as a base for the N-alkylation of indole in ionic liquid was 










4. Alkylation of indole from potassium hydroxide, alkyl/aryl halide in acetone was 











5. Synthesis of N-alkyl substituted indole in presence of sodium hydride in DMF was 










6. Dual nucleophilic catalysis with DABCO for the N-methylation of indoles was 
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7. B. Sebastian et al.9 have synthesized selective Ruthenium-catalyzed N-alkylation 

















8. The use of (NHC)CuI complex in combination with a N-heterocyclic carbene 
precursor as catalyst for the double carbonylation of aryl iodides and secondary 
amines solves the problem of using the precious metal Pd and phosphine ligands 























9. J. Zhua and coworkers11 have given one-pot synthesis of nitrogen-containing 















10. I. Bennacefa et al.12 have synthesized halogenated N,N-dialkylel-(2-phenyl-1H-










(1) (COCl)2, THF, 0
OC
(2) Amine, THF, 0OC
 
 
11. R. Gitto et al.13 have synthesized glyoxylamide derivatives containing N-
substituted isoquinoline nucleus. 
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12. One-step synthesis of N-alkyl-2-aryl-2-oxoacetamide derivatives was given by I. 
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THERAPEUTIC IMPORTANCE 
Indole-3-yl-glyoxylamide derivatives have been tested for various 








8. GABA-A receptor22 
9.  Antihypertensive23 
10. Cardiovascular24 
 
F. D. Settimo et al.25 have studied anxiolytic effects of N,N-dialkyl-2-phenylindol-
3-ylglyoxylamides (2) by modulation of translocator protein promoting neurosteroid 
biosynthesis. M. Gavish et al.26 and P. Casellas et al.27 have synthesized indole-3- 
glyoxamide derivatives in a variety of biological processes, including calcium 
homeostasis, lipid metabolism, mitochondrial oxidation, cell growth and differentiation, 
apoptosis induction, and regulation of immune functions. G. Primofiore et al.28 have 
synthesized N,N-dialkyl-2-phenylindol-3-ylglyoxylamides a new class of potent and 














R1 = R2 = (CH2)2CH3
R3 = NO2, CF3, H, F
R4 = H, NO2, OCH3, F, Cl
R5 = H, Cl, CH3
(2)  
 
N. A. Meanwell et al.29 have described the discovery of indole-3-glyoxamide (3) 
derivatives as the first small molecule inhibitors of the gp120-CD4 interaction (HIV-1 
attachment inhibition) that demonstrate potent antiviral activity in cell culture.30 
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Antibacterial activities of 3-indolylglyoxamide substituent have been explored in 

















R1 = H, CN, NO2, OCH3, Br
R2 = H, CH3
R3 = H, CH3
  X = CH, N(4)
 
 
A series of marine alkaloid 8,9-dihydrocoscinamide, (5) its analogues and 
indolylglyoxylamide derivatives have been synthesized and screened for their in vitro 















 = CH3 = SO2Ph
(5)  
 
I. Collins et al.31 have synthesized new class of N-(indol-3-ylglyoxylyl)piperidines 
(6) are high affinity agonists at the benzodiazepine binding site of human GABA-A 
receptor ion-channels, with modest selectivity for receptors containing the α1. 
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G. Primofiore and coworkers32 have synthesized N-(arylalkyl)indol-3-
ylglyoxylylamides (7) targeted as ligands of the benzodiazepine receptor, as well as 
biological evaluation and molecular modeling analysis of the structure activity 
















 V. W. Pike et al.33 have evaluated novel N-methyl-2-phenylindol-3-ylglyoxyl- 
amides (8) as a new chemo type of 18 kDa translocator protein-selective ligand suitable 















indol-3-yl]-N,N-dimethyl-2-(oxo)acetamide (9) compounds as 5-HT6 receptor modulators 
for use in medicaments was reported by M. V. Ramon et al.34 
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 W. Tao and coworkers35 have evaluated indole to azaindoles leading to the 
discovery of 1-(4-Benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-
yl)ethane-1,2-dione as a antiviral activity in HIV-1 infected subjects. J. Wang and 
coworkers36 have modified structure-activity relationship of a small molecule HIV-1 
inhibitor targeting the viral envelope glycoprotein gp120. M. Pascal et al.37 have 
synthesized N-aryl(indol-3-yl)glyoxamides as antitumor agents.  
Literature survey reveals that the compounds bearing glyoxamides moiety possess 
potential drug activity. Looking to the diversified biological activities we have 
synthesized some glyoxamides derivatives in order to achieving better therapeutic agents. 
These studies are described in following section. 
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SECTION-I 




Heterocyclic compounds bearing Indole-3-yl-glyoxylamide ring system are 
endowed with variety of biological activities. Our strategy is based on to develop a new 
bioactive entity especially with pharmacological activities bearing heterocyclic ring 
system. In view of our ongoing interest in the synthesis of some new Indole-3-yl-
glyoxylamide derivatives, we have under taken the condensation of 1-propyl-1H-indole-






















(ii)  Sec. amine
(i)  (COCl)2
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR 
and 13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Shimadzu-10AT. Elemental 
analysis of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned.  
 
[A] Preparation of 1-Propyl-1H-indole-2-carboxylic acid. 
To a stirred suspension of K2CO3 (2.72 g, 0.02 mol) and 1H-indole-2-carboxylic 
acid  (1.61 g, 0.01 mol) in dry DMF (10 ml), 1-bromopropane (1.18 ml, 0.013 mol) was 
added dropwise after 5 minute. The resultant solution was stirred for 5 hour at room 
temperature, and then poured onto crushed ice, the product was isolated and washed with 
water and hexane to give pure product. Yield: 93 %, mp 80-83 oC.  
 
[B] General procedure for the preparation of 3-[N,N-Dialkylamine(oxo)acetyl]-1-
propyl-1H-indole-2-carboxylic acids. 
To a stirred cooled (ice bath) solution of 1-propyl-1H-indole-2-carboxylic acid 
(2.03 g, 0.01 mol) in dry DCM (15 ml), oxalyl chloride (1.27 ml, 0.015 mol) was added 
dropwise in solution. The obtained solution was stirred at 0-5 oC for 10-15 minute then 
add TEA (1.68 ml, 0.012 mol) dropwise. The resulting solution was stirred at 0-5 oC for 
30.0 minute and then at 25-30 oC for 1 hour. Dark yellow colored was formed. The 
solvent was removed in vacuo, the residue was dissolved in dry DCM (12 ml) and 
different secondary amine (0.012 mol) dropwise. The reaction mixture was stirred at 0-
5 oC for 30.0 minute and then 25-30 oC for another 30.0 minute (monitored by TLC). The 
solvent was removed in vacuo. The product was dissolved in water and extracted with 
ethylacetate (25 ml × 3). The combined organic layers were washed with water followed 
by brine and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the 
solid was triturated with hexane and resulting precipitate was filtered, washed with 
hexane and dried to give analytical pure product. The physical constants of the product 
are recorder in Table-1a. 
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C18H22N2O4 330.37 80 0.51 
1c N N
 






342.38 89 0.38 





































356.41 78 0.60 
  
           TLC solvent system:- E.A. : Hexane = 6 : 4   
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ANALYTICAL DATA 
3-[Morpholin-4-yl(oxo)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1a). mp 168-
170 °C; Purity by HPLC: 94 %; IR (KBr): 3446 (O-H, str), 3023 (Ar, C-H str), 2947 (C-H 
str), 2805 (C-H str), 1706 (acid, C=O str), 1633 (amide, C=O str), 1528 (Ar, C=C str), 
1440 (Ar, C=C str), 1256 (C-H ban), 1152 (C-O str) cm-1; 1H NMR (400 MHz, CDCl3): δ 
ppm 0.92-0.96 (t, J=7.32 Hz, 3H, CH3), 1.07-1.25 (m, 2H, CH2), 1.63-1.75 (m, 4H, 
2CH2), 3.62-3.66 (t, J=7.08 Hz, 2H, CH2), 3.77-3.87 (m, 4H, 2CH2), 7.30-7.45 (m, 3H, 
ArH), 8.30-8.31 (d, J=7.92 Hz, 1H, ArH), 9.77 (s, 1H, OH). 13C NMR (100 MHz, 
CDCl3): δ ppm 10.28, 21.81, 41.89, 46.36, 66.27, 112.36, 116.38, 123.07, 123.85, 
126.41, 127.48, 129.99, 135.13, 159.00, 166.94, 187.66; MS: m/z = 344 [M]+; Anal. 
Calcd for C18H20N2O5: C, 62.78; H, 5.85; N, 8.13. Found: C, 62.67; H, 5.47; N, 8.09%. 
 
3-[(Diethylamino)(oxo)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1b). mp 133-
134 °C; Purity by HPLC: 91 %; IR (KBr): 3412, 3044, 2983, 2861, 1710, 1673, 1552, 
1444, 1287, 1175 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 0.86-0.89 (t, J=7.4 Hz, 3H, 
CH3), 1.29-1.34 (m, 6H, 3CH3), 1.51-1.60 (m, 2H, CH2), 3.41-3.44 (t, J=7.08 Hz, 2H, 
CH2), 3.55-3.61 (m, 4H, 2CH2), 7.28-7.30 (m, 1H, ArH), 7.32-7.36 (m, 1H, ArH), 7.45-
7.47 (d, J=8.2 Hz, 1H, ArH), 8.31-8.33 (d, J=8.0 Hz, 1H, ArH), 10.11 (s, 1H, OH). 13C 
NMR (100 MHz, CDCl3): δ ppm 10.17, 12.50, 13.73, 21.66, 39.35, 42.72, 66.95, 112.71, 
116.09, 122.99, 123.54, 125.99, 127.59, 130.06, 135.24, 158.88, 167.89, 188.32; MS: m/z 
= 330 [M]+; Anal. Calcd for C18H22N2O4: C, 65.44; H, 6.71; N, 8.48. Found: C, 65.36; 
H, 6.61; N, 8.37%. 
 
3-[(4-Phenylpiperazin-1-yl)(oxo)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1c). 
mp 153-155 °C; IR (KBr): 3502, 3101, 2961, 2852, 1708, 1678, 1533, 1456, 1248, 1156 
cm-1; MS: m/z = 419 [M]+; Anal. Calcd for C24H25N3O4: C, 68.72; H, 6.01; N, 10.02. 
Found: C, 68.59; H, 5.89; N, 9.95%. 
 
3-[Oxo(piperidin-1-yl)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1d). mp 189-190 
°C; IR (KBr): 3432, 3513, 3033, 2988, 2857, 1700, 1689, 1578, 1482, 1252, 1162 cm-1; 
MS: m/z = 343 [M+1]+; Anal. Calcd for C19H22N2O4: C, 66.65; H, 6.48; N, 8.18. Found: 
C, 66.53; H, 6.31; N, 8.06%. 
 
3-[(4-Methylpiperazin-1-yl)(oxo)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1e). 
mp 128-130 °C; IR (KBr): 3501, 3055, 2971, 2868, 1711, 1693, 1561, 1483, 1291, 1158 
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cm-1; MS: m/z = 357 [M]+; Anal. Calcd for C19H23N3O4: C, 63.85; H, 6.49; N, 11.76. 
Found: C, 63.77; H, 6.45; N, 11.70%. 
 
3-[(4-Ethylpiperazin-1-yl)(oxo)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1f). mp 
136-138 °C; IR (KBr): 3522, 3033, 2999, 2905, 1715, 1694, 1499, 1432, 1240, 1160 cm-
1; MS: m/z = 371 [M]+; Anal. Calcd for C20H25N3O4: C, 64.67; H, 6.78; N, 11.31. Found: 
C, 64.63; H, 6.72; N, 11.28%. 
 
3-[(N,N-Diisopropylamino)(oxo)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1g). 
mp 171-172 °C; IR (KBr): 3488, 3097, 2986, 2971, 1718, 1701, 1497, 1422, 1285, 1178 
cm-1; MS: m/z = 358 [M]+; Anal. Calcd for C20H26N2O4: C, 67.02; H, 7.31; N, 7.82. 
Found: C, 66.97; H, 7.28; N, 7.78%. 
 
3-[Oxo(pyrrolidin-1-yl)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1h). mp 201-
203 °C; IR (KBr): 3489, 3098, 2978, 2891, 1706, 1681, 1499, 1488, 1280, 1171 cm-1; 
MS: m/z = 328 [M]+; Anal. Calcd for C18H20N2O4: C, 65.84; H, 6.14; N, 8.53. Found: C, 
65.79; H, 6.09; N, 8.47%. 
 
3-[(2-Methylpiperidin-1-yl)(oxo)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1i). 
mp 191-193 °C; IR (KBr): 3569, 3099, 2966, 2898, 1720, 1696, 1583, 1467, 1281, 1184 
cm-1; MS: m/z = 356 [M]+; Anal. Calcd for C20H24N2O4: C, 67.40; H, 6.79; N, 7.86. 
Found: C, 67.35; H, 6.70; N, 7.83%. 
 
3-[(4-Methylpiperidin-1-yl)(oxo)acetyl]-1-propyl-1H-indole-2-carboxylic acid (1j). 
mp 149-150 °C; IR (KBr): 3546, 3084, 2997, 2951, 1717, 1687, 1576, 1455, 1279, 1187 
cm-1; MS: m/z = 356 [M]+; Anal. Calcd for C20H24N2O4: C, 67.40; H, 6.79; N, 7.86. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
HPLC of compound 1a 
Column :  YMC C-8 (4.6 x 150 mm, 5 µm particle size) 
Mobile phase :  Acetonitrile – 0.02M phosphate buffer pH 3.5 (60 : 40, v/v) 
Flow rate :  1.0 ml/min 
Minutes
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Mass spectrum of compound 1a 
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1H NMR spectrum of compound 1a 
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1H NMR spectrum of compound 1b 
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13C NMR spectrum of compound 1a 
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ANTIMICROBIAL ACTIVITY 
Biological evaluation of 3-[N,N-Dialkylamine(oxo)acetyl]-1-propyl-1H-indole-2-
carboxylic acids. 
All of the synthesized compounds (1a-j) were tested for their antibacterial and 
antifungal activity (MIC) in vitro by broth dilution method38-40 with two Gram-positive 
bacteria Staphylococcus aureus MTCC-96 and Streptococcus pyogenes MTCC 442, two 
Gram-negative bacteria Escherichia coli MTCC 443 and Pseudomonas aeruginosa 
MTCC 1688 and three fungal strains Candida albicans MTCC 227, Aspergillus Niger 
MTCC 282 and Aspergillus clavatus MTCC 1323 taking gentamycin, ampicillin, 
chloramphenicol, ciprofloxacin, norfloxacin, nystatin and greseofulvin as standard drugs. 
The standard strains were procured from the Microbial Type Culture Collection (MTCC), 
Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly synthesized 
compounds, defined as the lowest concentration of the compound preventing the visible 
growth, were determined by using micro dilution broth method according to NCCLS 
standards.38 
 
Minimal Inhibition Concentration [MIC] 
The main advantage of the Broth Dilution Method for MIC determination lies in 
the fact that it can readily be converted to determine the MIC as well. 
1. Serial dilutions were prepared in primary and secondary screening. 
2. The control tube containing no antibiotic is immediately subcultured (before 
inoculation) by spreading a loopful evenly over a quarter of plate of medium 
suitable for the growth of the test organism and put for incubation at 37 0C 
overnight.  
3. The MIC of the control organism is read to check the accuracy of the drug 
concentrations.  
4. The lowest concentration inhibiting growth of the organism is recorded as the 
MIC.  
5. The amount of growth from the control tube before incubation (which represents 
the original inoculums) is compared.  
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Methods used for primary and secondary screening 
Each synthesized compounds was diluted obtaining 2000 μg mL-1 concentration, 
as a stock solution. Inoculum size for test strain was adjusted to 108 cfu (colony forming 
unit) per milliliter by comparing the turbidity. 
 
Primary screen: In primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-
1 concentrations of the synthesized compounds were taken. The active synthesized drugs 
found in this primary screening were further tested in a second set of dilution against all 
microorganisms.  
 
Secondary screen: The compounds found active in primary screening were similarly 
diluted to obtain 200 μg mL-1, 100 μg mL-1, 50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 
6.250 μg mL-1 concentrations.  
 
Reading Result: The highest dilution showing at least 99 % inhibition zone is taken as 
MIC. The result of this is much affected by the size of the inoculums. The test mixture 
should contain 108 organism/mL.     
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Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1a 250 250 500 500 1000 1000 1000 
1b 250 100 250 500 200 500 500 
1c 62.5 100 500 500 >1000 250 250 
1d 100 500 250 250 250 500 200 
1e 100 250 100 250 500 250 250 
1f 500 200 200 100 1000 250 500 
1g 200 100 62.5 100 500 500 250 
1h 50 100 100 200 500 250 1000 
1i 250 500 200 500 250 200 1000 
1j 100 500 100 200 250 500 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
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INTRODUCTION 
Imidazolinone, a five membered heterocycle having 2-nitrogen atoms at the 1 and 
3-positions and C=O group at following positions: 2-oxo-imidazoline (1), 4-oxo-
imidazoline (2), 5-oxo-imidazoline (3).  Imidazolines are structurally related to guanidines 
and amidines. 
 Imidazolinone has been used extensively as a corrosion inhibitor of certain 
transition metals, such as copper. Preventing copper corrosion is important, especially in 















(1) (2) (3)  
 
The discovery of the 2-substituted-5-imidazolines dates back to the year 1888, 
when A. W. Hoffmann1 for the first time discovered 5-oxo-imidazoline by heating N1-
diacetyl ethylene diamine in a stream of dry hydrogen chloride and moreover the same 
compound was prepared by A. Ladenburg2 by the fusion of two equivalents of sodium 
acetate with one equivalent of ethylene diamine dihydrochloride. 
 
SYNTHETIC ASPECT 
Various methods have been reported for the synthesis of imidazolinones in 
literature.3 Aminolysis of oxazolone with amines led to the formation of imidazolinones 
which has been reported in literature.4 
1. Saxena et al.5 have synthesized new imidazolinone derivatives (4) by the reaction 















2. X. Huang et al.6 have synthesized some new imidazolinone derivatives (5) by the 
reaction of halide with acetonitrile in presence of K2CO3. 
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R1=n-Pr,R2=Aryl (5)  
 
3. A. V. Patel et al.7 have synthesized new Imidazolinone derivatives by 
conventional method. 
4. Z. Han et al.8 have synthesized 5-imidazolinone derivatives with 2-bromo- acetic 
acid as a starting material. 
 
 
REACTION MECHANISM  
 Azalactone reacts with variety of compounds such as water, alcohols, amines and 
hydrogen halides. Amides of α-acylamino acrylic acids obtained from the condensation of 














R' = NH2, Dry C5H5N/Abs.C2H5OH, K2CO3  
 
The ring closer can be affected under a variety of conditions. Substituted anilides 




Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various 
imidazolinone derivatives which have been used as adrenergic stimulants and tolazoline 
and phentolamine as adrenergic blocking agents. Various imidazolinones are known to 
exhibit a broad spectrum of biological activities such as: 
1. Antitubercular9 
2. Anti cancer10 
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P. Sah and coworkers19 have prepared some new imidazolinones and reported 
their antimicrobial and antileishmanial activities. K. M. Khan et al.20 have reported 
antibacterial and fungicidal activity of 5-oxo-imidazolines. Herbicidal activity of 
imidazolinone derivatives have been reported by Wang Ying et al.21 Y. Zhou et al.22 and 
A. Pai et al.23 have reported anticancer active analogues of 5-oxo-imidazolines. 
Imidazolinone derivatives which possess antifungal activity have been reported by M. D. 
Shah et al.24 Some new 5-oxoimidazolines as antimicrobial agents have been 
investigated P. S. Patel et al.25 V. Leroy and coworkers26 have prepared substituted 
imidazolone derivatives and reported their pharmaceutical use as inhibitors of protein 
kinases, particularly CDC7 and antiproliferative agents. N. Xue et al.27 have synthesized 










Work done from our laboratory 
 A. M. Vyas28 have synthesized 1-aryl-2-methyl-4-(8-hydroxyquinolin-7-yl 
methine)-5-imidazolones. Synthesis of some new imidazolones and 1,2,4-triazoles 
bearing benzo[b]thiophene nucleus as antimicrobial agents have been reported by K. M. 
Thakar.29 1-N-substituted benzalaminothiocarbonyl-2-methyl-4-(8'-hydroxyquinolin-7'-
yl)methine-5-imidazolones have been reported by A. M. Vyas.30  
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 Literature survey reveals that the compounds bearing imidazolones moiety 
possess potential drug activity. Looking to the diversified biological activities we have 
synthesized some imidazolinone derivatives in order to achieving better therapeutic 
agents. These studies are described in following section. 
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SECTION-I 




Various imidazolinone have resulted in many potential drugs and are known to 
possess a broad biological spectrum. In view of getting better therapeutic agents and 
considering the association of various biological activities with Indole-2-carbohydrazide 
nucleus, the preparation of imidazolone have been undertaken by the condensation of 1H-
indole-2-carbohydrazide with substituted azalactones which in turn have been prepared by 
































The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Shimadzu-10AT. Elemental 
analysis of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned. 
 
[A] Synthesis of 1H-Indole-2-carbohydrazide.31  
Methyl 1H-indole-2-carboxylate (1.75 g, 0.01 mol) in absolute ethanol (25 ml) 
was refluxed with 1.0 ml of hydrazine hydrate for 2 hour. After the completion of the 
reaction checked by TLC, the reaction mixture was cooled to room temperature. The 
separated solid was filtered, washed with cold ethanol and recrystallized from ethanol. 
Yield 98%, m.p 247-248 °C. 
   
[B] Synthesis of 4-Arylidene-2-phenyl-5-oxazolinones. 
These were prepared by the condensation of substituted benzaldehyde with 
benzoyl glycine in presence of sodium acetate and acetic anhydride as described by 
Vogel.32 
 
[C] General procedure for the preparation of N-[(4Z)-4-Arylidene-5-oxo-2-
phenyl-4,5-dihydro-1H-imidazol-1-yl]-1H-indole-2-carboxamides.  
To a mixture of 1H-indole-2-carbohydrazide (1.75 g, 0.01 mol) and different 4-
arylidene-2-phenyl-5-oxazolinones (0.01 mol) in a pyridine (15 ml) was refluxed for 8-10 
hour (monitoring by TLC). The excess of solvent was removed under reduced pressure 
and reaction mixture was poured on crushed ice. The product was isolated and 
crystallized from methanol to give analytical pure product. The physical constants of the 
product are recorded in Table-2a. 
 
[D] Biological evaluation of N-[(4Z)-4-Arylidene-5-oxo-2-phenyl-4,5-dihydro-1H-
imidazol-1-yl]-1H-indole-2-carboxamides. 
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-2b. 
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C25H17N5O4 451.43 68 0.43 
2c CH3 C26H20N4O2 420.46 74 0.53 
2d 
 
C25H18N4O2 406.43 78 0.36 
2e Cl
 






C25H17N5O4 451.43 70 0.62 
2g OH C25H18N4O3 422.43 68 0.66 
2h F
 
C25H17FN4O2 424.42 65 0.38 
2i O
CH3






C27H22N4O4 466.48 76 0.44 
   
           TLC solvent system:- E.A. : Hexane = 3 : 7 
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ANALYTICAL DATA 
N-[(4Z)-4-(2-Methoxybenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-
1H-indole-2-carboxamide (2a). mp 236-238 °C; Purity by HPLC: 99 %; IR (KBr): 3338 
(N-H str), 3059 (Ar, C-H str), 2926 (C-H str), 2847 (C-H str), 1647 (amide, C=O str), 
1591 (C=N str), 1570 (Ar, C=C str), 1508 (Ar, C=C str), 1271 (C-H ban), 1026 (C-N str), 
810 (C-H, o.p. ban) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 3.92 (s, 3H, OCH3), 6.84-
6.98 (m, 2H, ArH), 6.99-7.09 (m, 2H, ArH), 7.14-7.21 (m, 3H, ArH), 7.39-7.50 (m, 3H, 
ArH), 7.52-7.60 (m, 1H, ArH), 7.74-7.79 (m, 1H, ArH), 7.98 (s, 1H, C=CH), 8.05-8.07 
(d, J=7.12 Hz, 2H, ArH), 8.54 (s, 1H, NH), 10.75 (s, 1H, NH). 13C NMR (100 MHz, 
CDCl3): δ ppm 55.66, 115.20, 124.06, 124.21, 124.42, 126.10, 127.20, 127.29, 127.95, 
128.10, 128.95, 129.27, 129.40, 129.99, 130.08, 130.74, 137.27, 141.20, 157.35, 159.57, 
189.06; MS: m/z = 437 [M+1]+; Anal. Calcd for C26H20N4O3: C, 71.55; H, 4.62; N, 12.84. 
Found: C, 71.29; H, 4.47; N, 12.61%. 
 
N-[(4Z)-4-(4-Nitrobenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-1H-
indole-2-carboxamide (2b). mp 213-215 °C; Purity by HPLC: 96 %; IR (KBr): 3443, 
3068, 1697, 1591, 1522, 1445, 1260, 1040, 820 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 
7.42-7.52 (m, 3H, ArH), 7.54-7.63 (m, 3H, ArH), 7.65-7.75 (m, 1H, ArH), 7.84-7.85 (d, 
J=7.08 Hz, 1H, ArH), 8.09-8.13 (m, 2H, ArH), 8.24-8.27 (d, J=11.84 Hz, 2H, ArH), 8.35 
(s, 1H, C=CH), 8.52 (s, 1H, NH), 8.78-8.86 (m, 2H, ArH), 10.73 (s, 1H, NH). 13C NMR 
(100 MHz, CDCl3): δ ppm 115.72, 127.60, 127.80, 128.00, 129.74, 130.20, 130.41, 
130.65, 131.02, 131.72, 132.10, 132.40, 133.27, 133.62, 134.10, 137.60, 141.10, 157.48, 
160.12, 191.16; MS: m/z = 451 [M]+; Anal. Calcd for C25H17N5O4: C, 66.51; H, 3.80; N, 
15.51. Found: C, 66.25; H, 3.76; N, 15.42%. 
 
N-[(4Z)-4-(4-Methylbenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-1H-
indole-2-carboxamide (2c). mp 179-180 °C; IR (KBr): 3466, 3075, 1681, 1613,  1499, 
1402, 1261, 1025, 840 cm-1; MS: m/z = 420 [M]+; Anal. Calcd for C26H20N4O2: C, 74.27; 
H, 4.79; N, 13.33. Found: C, 73.95; H, 4.70; N, 13.21%. 
 
N-[(4Z)-4-Benzylidene-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-1H-indole-2-
carboxamide (2d). mp 163-165 °C; IR (KBr): 3469, 3076, 1706, 1646, 1576, 1466, 
1281, 1021, 746 cm-1; MS: m/z = 406 [M]+; Anal. Calcd for C25H18N4O2: C, 73.88; H, 
4.46; N, 13.78. Found: C, 73.58; H, 4.40; N, 13.67%.  
Studies on chemical… 
Imidazolones derivatives…                                       56 
N-[(4Z)-4-(4-Chlorobenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-1H-
indole-2-carboxamide (2e). mp 225-224 °C; IR (KBr): 3459, 3077, 1694, 1634, 1597, 
1464, 1261, 1013, 866 cm-1; MS: m/z = 440 [M]+; Anal. Calcd for C25H17ClN4O2: C, 
68.11; H, 3.89; N, 12.71. Found: C, 67.82; H, 3.81; N, 12.54%. 
 
N-[(4Z)-4-(3-Nitrobenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-1H-
indole-2-carboxamide (2f). mp 183-184 °C; IR (KBr): 3492, 3064, 1705, 1625,  1599, 
1406, 1242, 1039, 723 cm-1; MS: m/z = 452 [M+1]+; Anal. Calcd for C25H17N5O4: C, 
66.51; H, 3.80; N, 15.51. Found: C, 66.18; H, 3.75; N, 15.39%. 
 
N-[(4Z)-4-(4-Hydroxybenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-
1H-indole-2-carboxamide (2g). mp 151-153 °C; IR (KBr): 3469, 3003, 1691, 1589,  
1565, 1482, 1250, 1044, 716 cm-1; MS: m/z = 422 [M]+; Anal. Calcd for C25H18N4O3: C, 
71.08; H, 4.29; N, 13.26. Found: C, 70.84; H, 4.18; N, 13.08%. 
 
N-[(4Z)-4-(4-Fluorobenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-1H-
indole-2-carboxamide (2h). mp 138-139 °C; IR (KBr): 3454, 3086, 1712, 1602,  1546, 
1445, 1016, 747 cm-1; MS: m/z = 425 [M+1]+; Anal. Calcd for C25H17FN4O2: C, 70.75; H, 
4.04; N, 13.20. Found: C, 70.21; H, 3.98; N, 13.07%. 
 
N-[(4Z)-4-(4-Methoxybenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]-
1H-indole-2-carboxamide (2i). mp 173-174 °C; IR (KBr): 3394, 3074, 1688, 1592,  
1572, 1465, 1028, 727 cm-1; MS: m/z = 436 [M]+; Anal. Calcd for C26H20N4O3: C, 71.55; 
H, 4.62; N, 12.84. Found: C, 71.16; H, 4.51; N, 12.63%. 
 
N-[(4Z)-4-(2,5-Dimethoxybenzylidene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-
yl]-1H-indole-2-carboxamide (2j). mp 201-202 °C; IR (KBr): 3386, 3056, 1690, 1587,  
1585, 1464, 1024, 723 cm-1; MS: m/z = 467 [M+1]+; Anal. Calcd for C27H22N4O4: C, 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
HPLC of compound 2a 
Column :  YMC C-8 (4.6 x 150 mm, 5 µm particle size)   
Mobile phase :  Acetonitrile – 0.02M phosphate buffer pH 3.5 (60: 40, v/v). 
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Mass spectrum of compound 2a
 
 





















M. Wt. = 420.46
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1H NMR spectrum of compound 2a 
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1H NMR spectrum of compound 2b 
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13C NMR spectrum of compound 2a 
 
 

























Studies on chemical… 
Imidazolones derivatives…                                       62 





Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
2a 100 50 62.5 100 200 500 250 
2b 200 200 100 250 500 200 500 
2c 100 100 250 250 500 1000 1000 
2d 500 250 500 100 250 250 500 
2e 500 500 100 100 500 1000 1000 
2f 250 500 100 500 1000 250 500 
2g 250 100 200 200 >1000 200 250 
2h 200 250 100 500 500 1000 250 
2i 500 500 500 250 500 500 500 
2j 200 500 250 250 250 500 200 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
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INTRODUCTION  
Oxadiazoles belong to an important group of heterocyclic compounds 
having –N=C-O- linkage. It is well documented that oxadiazole system contains 















(1) (2) (3) (4)  
 
1,3,4-Oxadiazole is a heterocyclic molecule with oxygen atom at 1 and two 
nitrogen atoms at 3 and 4 position. 1,3,4-Oxadiazole is a thermally stable aromatic 
molecule.1 They have been known for about 80 years it is only in the last decade 
that investigations in this field have been intensified. This is because of large number 
of applications of 1,3,4-oxadiazoles in the most diverse areas viz. drug 
synthesis, dye stuff industry, heat resistant materials, heat resistant polymers and 
scintillators. Reviews of the relevant literature prior to 1965 are available.2 
 
SYNTHETIC ASPECT 
Most 1,3,4-oxadiazoles are best obtained by synthesis from acyclic precursors. 
Such reactions are ‘one bond’ or ‘two bond’ cyclization. Different methods for the 
synthesis have been cited in literature.3-8  
1. B. Chandrakantha et al.9 have synthesized oxadiazoles (5) by the reaction of 

















2. D. Ramesh and B. Sreenivasan10 have synthesized 1,3,4-oxadiazoles (6) from 
semicarbazide in presense of POCl3. 
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3. K. Mogilaiah and B. Sakram11 have prepared 1,3,4-oxadiazoles (7) from 
acetophenone-2-trifluoromethyl-1,8-naphthyridine-3-carbonyl hydrazone in 

















4. Yu Yuve have reported microwave-assisted synthesis protocol of oxadiazoles (8) 


















5. L. Somogyi13 synthesized 1,3,4-oxadiazoles (9) from several steps, from aryl 


















6. Silica sulfuric acid catalyst used for the rapid and ecofriendly synthesis of 1,3,4-

















7. Green chemistry and one-pot, solvent-free using microwave mediated synthesis of 
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2,5-Disubstituted-1,3,4-oxadiazole derivatives have been tested for various 
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10. Herbicidal25 
11. Hypoglycemic26 
12. Hypnotic and Sedative27 
13. MAO inhibitor28 
14. Insecticidal29 
 
 S. R. Bishnoi et al.30 have screened oxadiazoles for their antimicrobial activity. 
A. El-Azzouny et al.31 have synthesized 1,3,4-oxadiazole derivatives and evaluated for 
their analgesic, anti-inflammatory, ulcerogenic effects and inhibitory activity on 
plasma prostaglandin E2  (PGE2) Level. 
 S. V. Bhandari et al.32 have reported 1,3,4-oxadiazoles for their anti-
inflammatory activity. Song Cao et al.33 have investigated some oxadiazoles possessing 
insecticidal activity. G. V. Suresh Kumar et al.34 have discovered oxadiazole derivatives 
and reported their antimycobacterial activity. Ali Almasired et al.35 have prepared 1,3,4- 
oxadiazoles of type (12) as anticonvulsant agent. Meria Grazia Mamolo et al.36 have 
synthesized 3-substituted-5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-ones of type (13) 















Krishna Kant Jha et al.37 have reported antimicrobial activity of oxadiazole 
derivatives. J. A. Christopher et al.38 have documented human immunodeficiency virus 
(HIV) infection of 1,3,4-oxadiazole derivatives. S. J. Gilani et al.39 have synthesized 
some oxadiazoles as anti-inflammatory and analgesic agents. K. Subrahmanya Bhat et 
al.40 have prepared new fluorine containing 1,3,4-oxadiazoles (14) and reported them as 
potential antibacterial and anticancer agents. T. P. Mohan et al.41 have synthesized 
2,5-disubstituted-1,3,4-oxadiazole derivatives (15) and screened for their insecticidal 
activity. 
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 Ronald Kim et al.42 have discovered oxadiazole derivatives useful as protease 
inhibitors. Mohd Amir and Kumar Shikha43 have documented anti-inflammatory, 
analgesic and ulcerogenic activity of some newly synthesized oxadiazoles. A. Ali et 
al.44 have investigated some oxadiazole derivatives possessing antimicrobial and 
anti-HIV-1 activity. A. Sherif et al.45 have reported oxadiazoles as potential 
antitumor and anti-HIV agents. A. Zarghi et al.46 have synthesized R-substituted-5-
(2-benzyloxyphenyl)-1,3,4-oxadiazoles (16) possessing anticonvulsant activity. M. 

















Work done from our laboratory 
K. M. Thaker48 have synthesized 2-(3',5'-dichlorobenzo[b]thiophen-2'-yl)-5-
aryl-1,3,4-oxadiazoles in the presence of aromatic acid. S. L. Vasoya49 reported facile 
synthesis of some new acetyl oxadiazoles bearing benzo[b]thiophene nucleus as a 
potent biological active agent. Preparation and antimicrobial activity of 2-aryl-5-(5',7'-
diiodo-8'-quinolinoxy)-1,3,4-oxadiazoles have been reported by H. S. Joshi.50 Thus 
with an effort to capitalize the biological potential of the heterocyclic system and to 
provide more interesting compounds for biological screening, we have under taken the 
synthesis of several oxadiazoles which has been described as under. 
 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-(5-ARYL-              
1,3,4-OXADIAZOL-2-YL)-1-PROPYL-1H-INDOLES. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-(5-ARYL-1,3,4-
OXADIAZOL-2-YL)-1-PROPYL-1H-INDOLES. 
 
Synthesis of 1,3,4-oxadiazole derivatives has attracted considerable attention 
in view of therapeutic applications. Looking to this, the synthesis of 1,3,4-
oxadiazoles was undertaken by the condensation of different aromatic acid with 1-
propyl-1H-indole-2-carbohydrazide in presence of phosphorous oxychloride, as 




























The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 




Studies on chemical…                 
Oxadiazole derivatives…                                                                                                    71 
EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Shimadzu-10AT. Elemental 
analysis of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned.  
 
[A] Synthesis of 1-Propyl-1H-indole-2-carbohydrazide. 
Methyl 1-propyl-1H-indole-2-carboxylate (2.17 g, 0.01 mol) in absolute ethanol 
(25 ml) was refluxed with hydrazine hydrate (1.0 ml) for 2 hour. After the completion of 
the reaction checked by TLC, the reaction mixture was cooled to room temperature. The 
separated solid was filtered, washed with cold ethanol and crystallized from ethanol. 
 
[B] General procedure for the preparation of 2-(5-Aryl-1,3,4-oxadiazol-2-yl)-1-
propyl-1H-indole. 
A mixture of 1-propyl-1H-indole-2-carbohydrazide (2.17 g, 0.01 mol) and 
different aryl acids (0.01 mol) in phosphorous oxychloride (10 ml), was refluxed with 
continuous stirring. After completion the reaction (8-10 hour monitoring by TLC), the 
content was cooled to room temperature then add ice cooled water and neutralized with 
sodium bicarbonate solution. Then extracted into ethyl acetate. The organic extracts was 
washed with water (2 x 10 ml), dried with Na2SO4, solvent was removed in vacuo and the 
resulting crude product was purified by colum chromatography to give the analytical pure 
compound. The physical constants of the product are recorded in Table-3a. 
 
[C] Biological evaluation of 2-(5-Aryl-1,3,4-oxadiazol-2-yl)-1-propyl-1H-indole. 
 Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
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382.80 71 0.36 
 











319.35 78 0.61 
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ANALYTICAL DATA 
2-[5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-1-propyl-1H-indole (3a). mp 133-135 °C; 
Purity by HPLC: 87 %; IR (KBr): 3001 (Ar, C-H str), 2933 (C-H str), 2908 (C-H str), 
1626 (oxadiazole, C=N str ),  1585 (Ar, C=C str), 1533 (Ar, C=C str), 1465 (C-O-C str), 
1172 (N-N str), 748 (C-H, o.p. ban) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 0.96-1.00 
(t, J=7.44 Hz, 3H, CH3), 1.87-1.96 (m, 2H, CH2), 4.70-4.74 (t, J=7.48 Hz, 2H, CH2), 
7.16-7.20 (m, 1H, ArH), 7.33-7.37 (m, 2H, ArH), 7.44-7.55 (m, 3H, ArH), 7.70-7.72 (d, 
J=8.0 Hz, 1H, ArH), 8.03-8.05 (m, 1H, ArH), 8.11-8.12 (m, 1H, ArH). 13C NMR (100 
MHz, CDCl3): δ ppm 11.28, 23.57, 46.75, 107.13, 110.53, 120.75, 122.09, 122.33, 
124.67, 125.07, 125.33, 126.93, 126.94, 130.52, 131.84, 135.27, 139.10, 159.87, 162.44; 
MS: m/z = 340 [M+2]+; Anal. Calcd for C19H16ClN3O: C, 67.56; H, 4.77; N, 12.44. 
Found: C, 66.89; H, 4.68; N, 12.36%. 
 
2-[5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-yl]-1-propyl-1H-indole (3b). mp 148-149 °C; 
Purity by HPLC: 86 %; IR (KBr): 3064, 2972, 2859, 1700, 1643, 1576, 1435, 1141, 720 
cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 0.97-1.00 (t, J=7.28 Hz, 3H, CH3), 1.89-1.99 
(m, 2H, CH2), 4.91-4.95 (t, J=7.48 Hz, 2H, CH2), 7.33-7.37 (m, 1H, ArH), 7.50-7.54 (m, 
3H, ArH), 7.62-7.63 (d, J=7.08 Hz, 1H, ArH), 7.87-7.89 (d, J=7.4 Hz, 1H, ArH), 8.20-
8.23 (m, 2H, ArH), 8.28-8.30 (m, 1H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 11.10, 
22.17, 47.10, 109.00, 112.00, 121.15, 121.50, 121.99, 126.01, 126.50, 126.94, 128.30, 
128.55, 131.01, 132.31, 136.70, 140.57, 160.13, 164.17; MS: m/z = 348 [M]+; Anal. 
Calcd for C19H16N4O3: C, 65.51; H, 4.63; N, 16.08. Found: C, 65.18; H, 4.57; N, 15.93%. 
 
2-[5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1-propyl-1H-indole (3c). mp 123-125 
°C; IR (KBr): 3030, 2964, 2853, 1642,  1612,  1581, 1471, 1156, 819 cm-1; MS: m/z = 
334 [M+1]+; Anal. Calcd for C20H19N3O2: C, 72.05; H, 5.74; N, 12.60. Found: C, 71.35; 
H, 5.64; N, 12.55%. 
 
4-[5-(1-Propyl-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl]aniline (3d). mp 117-119 °C; IR 
(KBr): 3074, 2987, 2851, 1645, 1612, 1585, 1468, 1184, 820 cm-1; MS: m/z = 318 [M]+; 
Anal. Calcd for C19H18N4O: C, 71.68; H, 5.70; N, 17.60. Found: C, 71.28; H, 5.63; N, 
17.54%. 
 
2-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-1-propyl-1H-indole (3e). mp 109-111 °C; 
IR (KBr): 3081, 2975, 2844, 1641, 1579, 1556, 1464, 1202, 750 cm-1; MS: m/z = 338 
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[M+1]+; Anal. Calcd for C19H16ClN3O: C, 67.56; H, 4.77; N, 12.44. Found: C, 67.20; H, 
4.61; N, 12.33%. 
 
2-[5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-yl]-1-propyl-1H-indole (3f). mp 178-179 °C; 
IR (KBr): 3080, 2983, 2867, 1629, 1572, 1525, 1462, 1245, 1196, 830 cm-1; MS: m/z = 
348 [M]+; Anal. Calcd for C19H16N4O3: C, 65.51; H, 4.63; N, 16.08. Found: C, 65.03; H, 
4.48; N, 15.83%. 
 
2-[5-(4-Fluorophenyl)-1,3,4-oxadiazol-2-yl]-1-propyl-1H-indole (3g). mp 165-167 °C; 
IR (KBr): 3077, 2978, 2863, 1625, 1609, 1563, 1464, 1238, 1142, 870 cm-1; MS: m/z = 
323 [M+2]+; Anal. Calcd for C19H16FN3O: C, 71.01; H, 5.02; N, 13.08. Found: C, 70.65; 
H, 5.00; N, 12.91%. 
 
2-[5-(2-Chloro-5-nitrophenyl)-1,3,4-oxadiazol-2-yl]-1-propyl-1H-indole (3h). mp 139-
141 °C; IR (KBr): 2962, 2854, 1603, 1545, 1542, 1452, 1260, 1146 cm-1; MS: m/z = 383 
[M+1]+; Anal. Calcd for C19H15ClN4O3: C, 59.61; H, 3.95; N, 14.64. Found: C, 59.35; H, 
3.87; N, 14.54%. 
 
1-Propyl-2-[5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl]-1H-indole (3i). mp 141-143 °C; IR 
(KBr): 3075, 2964, 2853, 1721, 1601, 1581, 1423, 1149, 720 cm-1; MS: m/z = 304 [M]+; 
Anal. Calcd for C18H16N4O: C, 71.04; H, 5.30; N, 18.41. Found: C, 70.65; H, 5.07; N, 
18.37%. 
 
2-[5-(1-Propyl-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl]phenol (3j). mp 184-186 °C; IR 
(KBr): 3061, 2951, 2872, 1689, 1589, 1579, 1462, 1099, 755 cm-1; MS: m/z = 319 [M]+; 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
HPLC of compound 3a  
Column :  Phenomenex Luna C8 (2) (250mm x 4.6mm i.d., 5 μm particle size)   
Mobile phase :  Acetonitrile – 0.02M phosphate buffer pH 3.5 (60: 40, v/v). 
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Mass spectrum of compound 3a 
 
 
















M. Wt. = 333.38
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1H NMR spectrum of compound 3a 
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1H NMR spectrum of compound 3b 
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13C NMR spectrum of compound 3a 
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Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
3a 500 500 200 250 1000 250 500 
3b 100 200 250 62.5 500 500 1000 
3c 250 250 100 200 1000 500 500 
3d 50 100 500 250 200 250 200 
3e 250 200 500 100 250 1000 500 
3f 500 250 250 200 >1000 500 200 
3g 250 100 100 500 500 250 500 
3h 250 500 500 200 250 500 1000 
3i 200 500 200 150 250 500 500 
3j 62.5 100 100 100 200 200 250 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
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Introduction 
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INTRODUCTION 
Bridge nitrogen containing fused heterocycles represents important building 
blocks in both natural and synthetic bioactive compounds which have been shown to 
possess diverse therapeutic activities.1 Hence they are interesting target to be prepared to 
our research on medicinally interesting heterocyclic entities. Aza-indolizine are of two 








The aza-indolizine contains a phenyl ring fused to a imidazole ring is indicated in 
the structure, hence it is also known as imidazo[1,2-a]pyridine.2 Several procedure for 
their synthesis have been extensively studied. Such studies have been stimulated by 
various promising applications, especially in the case of bridgehead nitrogen containing 
fused heterocyclic entities. 
The constitution of imidazo[1,2-a]pyridine was reviewed by W. L. Mosby3 in 
1961. Imidazo[1,2-a]pyridine derivatives not only known for their pharmacological 
applications, they are also used in disperse dyes.4 
 
SYNTHETIC ASPECT 
Classical methods have been reported in the literature for the synthesis of 
imidazo[1,2-a]pyridines. The procedure for synthesizing imidazo[1,2-a]pyridines have 
been described as under. 
1. The synthesis of imidazo[1,2-a]pyridine from 2-aminopyridine with ω-




2. 2-Acetylimidazo[1,2-a]pyridine6 can be constructed by the cyclocondensation of 
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3. Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent elimination of 











4. Shankarappa A Biradar8 have synthesized 6-bromo-2-(3,4-dichlorophenyl) 
imidazo[1,2-a]pyridine using microwave irradiation from 5-bromo-2-

















5. Jumat Salimon et al.9 synthesized imidazo[1,2-a]pyridine-3(2H)-one and 3-
















6. Synthesis of imidazo[1,2-a]pyridines using catalytic zinc chloride microwave 
irradiation from 2-aminopyridine and aryl aldehyde, aryl nitrile reported by 
Amanda L. Rousseau.10 
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7. Synthesis of Cu(OTf)2-catalyzed imidazo[1,2-a]pyridines from a-diazoketones 














8. Guchhait and coworkers12 reported towards molecular diversity: dealkylation of 
tert-butyl amine in Ugi-type multicomponent reaction product establishes tert-














9. Zhu Dongjian et al.13 have synthesized imidazo[1,2-a]pyridines from 2-
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The majority of imidazo[1,2-a]pyridine have been synthesized by the reaction of 
2-aminopyridine with a a-halocarbonyl compound which form oniumhalide which is 




 Imidazo[1,2-a]pyridines are potential bioactive agents due to their wide spectrum 
of therapeutic importance. A large number of substituted imidazo[1,2-a]pyridine 
derivatives are prepared and tested for varieties of biological activities such as, 
1. Antiinflammatory14 




6. Antifungal agents21 
7. Antibacterials22,23 
8. Hypnotic24 
9. Gastric antisecretory25 
10. Antimalarial26 
11. Anticancer27 
12. Anticytomegalo-zoster and antivaricellazoster virus28 
 
Alexander C. Humphries and coworkers29 have synthesized 8-fluoro imidazo[1,2-
a]pyridine derivatives (7) and evaluated as a bioisosteric replacement for imidazo[1,2-
a]pyridine in an allosteric modulator ligand of the GABA-A receptor. Carlos Jaramillo, 
and coworkers30 reported stereo dynamics of Ar–CO rotation and conformational 
preferences of 2-amino-3-(2,4-difluorobenzoyl)-imidazo[1,2-a]pyridine. I. Aramori et 
al.31 have been synthesized imidazo[1,2-a]pyridine derivatives which are highly potent 
and selective non-peptide bradykinin receptor antagonist (8). 
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(7) (8)  
 
Several imidazo[1,2-a]pyridine nucleus already in market which include 
alpidem32 [a ligand of both the central benzodiazepine receptors and the peripheral type 
(Mitochondrial) benzodiazepine receptor] has sedative and anxiolytic properties and 
zolpidem32 [a selective ligand for the central benzodiazepine receptor] is a hypnotic drug. 
Both alpidem and zolpidem have higher affinity for benzodiazepine-1 than for 




















James J. Kaminski and coworkers35 have investigated imidazo[1,2-a]pyridine 
derivative 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine (9) for 
an antiulcer activity. On the basis of the reported metabolism of zolimidine, they reported 












Brian A. Johns et al.36 and Chaouni-Bendallah A. et al.37 synthesized a novel 
imidazo[1,2-a]pyridines (10) with potent activity against Herpes Simplex viruses. J. T. 
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Starr et al.38 have synthesized 5-(2-pyrimidinyl)-imidazo[1,2-a]pyridines (11) from 2-




















Sebastien Follot et al.39 have synthesized 2-(4-fluorophenyl)-6-iodo-3-pyridin-4- 
limidazo[1,2-a]pyridine (12) from 6-iodo-2-(4-fluorophenyl)imidazo[1,2-a]pyridine and 
evaluated as anti-apoptosis agents.  Imidazo[1,2-a]pyridine units appear as important 
building blocks in both natural and synthetic bioactive compounds40-42 and recognition on 









Mohamed A. Ismail and coworkers43 have synthesized some newer diamine 
imidazo[1,2-a]pyridine (13), 5,6,7,8-tetrahydo imidazo[1,2-a]pyridines and their 
corresponding N-hydroxy and N-methoxy analogues and evaluated against Trypanosoma 
b. rhodesiense (T. B. rhodesiense) and Plasmodium falciparum (P. falciparum).  Luke R. 
Odell and coworkers44 have synthesized 6-substituted 3-amino-imidazo[1,2-a]pyridines 
(14) which has active against Mycobacterium tuberculosis glutamine synthetase 
inhibitors.  R. B. Lacerda and coworkers45 have find out a novel analgesic and anti-
inflammatory 3-arylamine- imidazo [1,2-a] pyridine. 
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Work done from our laboratory 
M. J. Ladani et al.46 reported oxopyrimidines and thiopyrimidines of 2-(2,4-
dichlorophenyl)imidazo[1,2-a]pyridin-3-carbaldehyde and their biological study. 
Thus the important role displayed by imidazo[1,2-a]pyridine and its derivatives 
for various therapeutic and biological activities prompted us to synthesize some 
Glyoxylamide, Mannich base and Bis-Imidazo[1,2-a]Pyridin derivatives bearing 
Imidazo[1,2-a]pyridine moiety in order to achieve compounds having better therapeutic 
activities described as in the following parts. 
 
 
STUDIES ON IMIDAZO[1,2-a]PYRIDINE DERIVATIVES 
 
PART-I: STUDIES ON IMIDAZO[1,2-a]PYRIDINE-3-YL-GLYOXYLAMIDE    
  DERIVATIVES 
PART-II: STUDIES ON MANNICH BASE DERIVATIVES  
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INTRODUCTION     
Imidazo[1,2-a]pyridine-3-yl-glyoxylamide derivatives having nitrogen-bridgehead 
fused heterocycles containing an imidazole ring. It is a common structural motif in 
pharmacologically important molecules, with activities spanning a diverse range of 
targets.1,2 The diversity, efficiency and rapid access to small and highly functionalized 
organic molecules makes this approach of central current interest in the construction of 













In recent year glyoxylamide derivatives have gained lot of interest because of their 
prominent pharmaceutical properties.  
 
SYNTHETIC ASPECT 
Various methods for the preparation of imidazo[1,2-a]pyridine-3-yl-glyoxylamide 
derivatives have been cited in literature, some of the methods are as under. 
1. R. Max and coworkers5 have synthesized imidazopyridinylacetamide derivatives 

















2. T. Eszter et al.6 have synthesized primary amide and keto amide via palladium-














3. B. Roman et al.7 reported mild and efficient conversion of nitriles to amides with 
basic urea-hydrogen peroxide adduct.  








4. L. K. Tin et al.8 reported catalytic hydration of nitriles to amides with manganese 










See Part-A, Part-I, Section-I, Therapeutic importance 
 
Looking to the diversified biological activities we have synthesized some 
glyoxylamide derivatives in order to achieving better therapeutic agents. These studies are 
described in following section. 
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SECTION-I 




The discovery of Imidazo[1,2-a]pyridine-3-yl-glyoxylamide derivatives as potent 
biologically active agent has led to the exploration of large number of structural variants, 
containing imidazo[1,2-a]pyridine-3-yl-glyoxylamide moiety as an invariable ingredient. 
In view of these reports, we have synthesize imidazo[1,2-a]pyridine-3-yl-glyoxylamide 
derivatives by the condensation of 2-(4-fluorophenyl)-6-methylimidazo[1,2-a]pyridine 


























The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Shimadzu-10AT. Elemental 
analysis of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned.  
 
[A] Synthesis of 2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-a]pyridine.  
 A solution of 5-methylpyridin-2-amine (1.08 g, 0.01 mol) in methanol (10 ml) 
was added to 2-chloro-1-(4-fluorophenyl)ethanone (1.72 g, 0.01 mol) and the reaction 
mixture was refluxed with stirring for 6 hour in the presence of catalytic amount of TEA. 
After the completion of reaction (monitoring by TLC), cool the content, the solid 
separated was filtered and dried in vacuo. Yield 68%, m.p 192 °C, Anal. Calcd. for 
C14H11FN2: Require: C, 74.32, H, 4.90, N, 12.38 %; Found: C, 74.30, H, 4.89, N, 12.35 
%. MS: m/z = 226. 
 
[B] General procedure for the preparation of 1-[2-(4-Fluorophenyl)-6-
methylimidazo[1,2-a]pyridin-3-yl]-2-(N,N-dialkylamine-4-yl)ethane-1,2-
diones. 
To a stirred solution of oxalyl chloride (1.01 ml, 0.012 mol) in dry DCM (10 ml), 
2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-a]pyridine (2.26 g, 0.01 mol) was added 
portion wise in solution. The obtained solution was stirred at room temperature for 10-15 
minute and then added TEA (1.22 ml, 0.012 mol) dropwise. The resulting mixture was 
stirred 25-30 oC for 2 hour dark yellow colored was formed. The solvent was removed in 
vacuo, the residue was dissolved in dry DCM (12 ml) and different secondary amine 
(0.015 mol) was added dropwise. The reaction mixture was stirred at 0 oC for 30.0 minute 
and then 25-30 oC for another 30.0 minute (monitored by TLC). The solvent was removed 
in vacuo. The product was extracted with ethyl acetate and the organic layers washed 
with water, dried over anhydrous Na2SO4. The solvent was removed in vacuo and the 
solid was triturated with hexane and resulting precipitate was filtered, washed with 
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hexane and dried to give analytical pure product. The physical constants of the product 
are recorded in Table-4a. 
 
[C] Biological evaluation of 1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a] 
pyridin-3-yl]-2-(N,N-dialkylamine-4-yl)ethane-1,2-diones. 
 Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 




























Studies on chemical… 
Glyoxylamide derivatives…                                                                                                                99 
























353.59 81 0.36 
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ethane-1,2-dione (4a). mp 196-198 °C; Purity by HPLC: 97 %; IR (KBr): 3116 (Ar, C-H 
str), 2979 (C-H str), 2942 (C-H str), 1729 (ketone, C=O str), 1708 (amide, C=O str), 1627 
(C=N str),  1528 (Ar, C=C str), 1442 (Ar, C=C str), 1254 (C-N str), 1090 (C-F) cm-1; 1H 
NMR (400 MHz, CDCl3): δ ppm 2.48 (s, 3H, CH3), 3.14-3.19 (m, 4H, CH2), 3.43-3.49 
(m, 4H, CH2), 7.15-7.20 (m, 2H, ArH), 7.50-7.52 (m, 1H, ArH), 7.60-7.65 (m, 2H, ArH), 
7.71-7.73 (d, J=9.08 Hz, 1H, ArH), 9.57 (s, 1H, ArH). 13C NMR (100 MHz, CDCl3): δ 
ppm 18.51, 40.84, 45.90, 65.97, 114.98, 115.20, 116.79, 118.52, 126.31, 127.41, 129.06, 
129.09, 132.01, 132.09, 134.07, 147.13, 156.41, 162.41, 164.46, 164.90, 180.61; MS: m/z 
= 368 [M+1]+; Anal. Calcd for C20H18FN3O3: C, 65.39; H, 4.94; N, 11.44. Found: C, 
64.87; H, 4.87; N, 11.32%. 
 
N,N-Diethyl-2-[2-(4-fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-
oxoacetamide (4b). mp 279-281 °C; Purity by HPLC: 99 %; IR (KBr): 3061, 2985, 2857, 
1711, 1687, 1596,  1573, 1456, 1122, 1082 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 
1.30-1.34 (t, J=7.48 Hz, 6H, CH3), 2.45 (s, 3H, CH3), 3.50-3.55 (q, J=7.12 Hz, 4H, CH2), 
7.07-7.10 (m, 2H, ArH), 7.47-7.50 (m, 1H, ArH), 7.59-7.62 (m, 2H, ArH), 7.69-7.71 (d, 
J=9.88 Hz, 1H, ArH), 9.42 (s, 1H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 12.61, 
14.41, 20.15, 39.38, 41.44, 114.30, 115.60, 116.85, 118.11, 126.30, 127.41, 129.10, 
129.15, 132.22, 132.30, 134.27, 147.13, 157.42, 162.81, 164.46, 164.90, 182.11; MS: m/z 
= 354 [M+1]+; Anal. Calcd for C20H20FN3O2: C, 67.97; H, 5.70; N, 11.89. Found: C, 
67.37; H, 5.63; N, 11.81%. 
 
1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-(4-phenylpiperazin-4-
yl)ethane-1,2-dione (4c). mp 223-225 °C; IR (KBr): 3088, 2976, 2864, 1702, 1683, 
1601, 1589, 1471, 1134, 1084 cm-1; MS: m/z = 443 [M+1]+; Anal. Calcd for 
C26H23FN4O2: C, 70.57; H, 5.24; N, 12.66. Found: C, 70.06; H, 5.14; N, 12.57%. 
 
1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-(piperidin-1-yl)ethane-
1,2-dione (4d). mp 193-195 °C; IR (KBr): 3070, 2968, 2842, 1718, 1699, 1581, 1578, 
1459, 1113, 1079 cm-1; MS: m/z = 356 [M]+; Anal. Calcd for C21H20FN3O2: C, 69.03; H, 
5.52; N, 11.50. Found: C, 68.84; H, 5.43; N, 11.41%. 
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1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-(4-methylpiperazin-1-
yl)ethane-1,2-dione (4e). mp 275-277 °C; IR (KBr): 3084, 2951, 2823, 1710, 1681, 
1600, 1589, 1423, 1196, 1089 cm-1; MS: m/z = 380 [M]+; Anal. Calcd for C21H21FN4O2: 
C, 66.30; H, 5.56; N, 14.73. Found: C, 65.78; H, 5.40; N, 14.58%. 
 
1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-(4-ethylpiperazin-1-yl) 
ethane-1,2-dione (4f). mp 212-214 °C; IR (KBr): 3075, 2956, 2846, 1699, 1680, 1586, 
1579, 1485, 1096, 1086 cm-1; MS: m/z = 394 [M]+; Anal. Calcd for C22H23FN4O2: C, 
66.99; H, 5.88; N, 14.20. Found: C, 66.26; H, 5.73; N, 14.01%. 
 
1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-(N,N-diisopropyl-1-yl) 
ethane-1,2-dione (4g). mp 187-189 °C; IR (KBr): 3082, 2958, 2875, 1701, 1689, 1596, 
1567, 1489, 1118, 1076 cm-1; MS: m/z = 381 [M]+; Anal. Calcd for C22H24FN3O2: C, 
69.27; H, 6.34; N, 11.02. Found: C, 68.53; H, 6.13; N, 10.88%. 
 
1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-(pyrrolidin-1-yl) 
ethane-1,2-dione (4h). mp 238-239 °C; IR (KBr): 3089, 2971, 2853, 1709, 1700, 1588, 
1564, 1443, 1191, 1087 cm-1; MS: m/z = 352 [M+1]+; Anal. Calcd for C20H18FN3O2: C, 
68.36; H, 5.16; N, 11.96. Found: C, 67.57; H, 5.05; N, 11.79%. 
 
1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-(2-methylpiperidin-1-
yl)ethane-1,2-dione (4i). mp 166-168 °C; IR (KBr): 3070, 2954, 2856, 1706, 1602, 1582, 
1556, 1457, 1166, 1081 cm-1; MS: m/z = 379 [M]+; Anal. Calcd for C22H22FN3O2: C, 
69.64; H, 5.84; N, 11.07. Found: C, 69.06; H, 5.71; N, 10.86%. 
 
1-[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]-2-(4-methylpiperidin-1-
yl)ethane-1,2-dione (4j). mp 144-145 °C; IR (KBr): 3071, 2952, 2864, 1708, 1694, 1584, 
1571, 1458, 1184, 1089 cm-1; MS: m/z = 379 [M]+; Anal. Calcd for C22H22FN3O2: C, 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
HPLC of compound 4a  
Column :  Phenomenex Luna C8 (2) (250mm x 4.6mm i.d., 5 μm particle size) 
Mobile phase :  Acetonitrile – 0.02M phosphate buffer pH 3.5 (40: 60, v/v). 
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Mass spectrum of compound 4a  
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1H NMR spectrum of compound 4a 
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1H NMR spectrum of compound 4b 
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13C NMR spectrum of compound 4a 
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Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
4a 100 200 250 250 1000 >1000 >1000 
4b 200 200 200 100 250 500 250 
4c 100 100 100 200 500 500 200 
4d 200 250 100 100 250 1000 1000 
4e 250 200 50 200 >1000 1000 500 
4f 500 100 250 100 1000 250 200 
4g 250 200 500 500 500 500 250 
4h 250 500 500 250 250 200 1000 
4i 200 200 100 100 500 200 500 
4j 500 200 250 200 200 250 200 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
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INTRODUCTION 
Mannich bases containing bridged N-atom exhibit pronounced biological 
activities. The study of mannich reaction attracted a great deal of attention to the chemists 
because it plays a vital role due to their wide range of biological and industrial 
applications. Mannich bases are also employed as intermediate in chemical synthesis.1-3 
Much interest has been focused on the synthesis of mannich bases due to its wide 
a variety of pharmacological activities. Mostly, they are found to be antineoplastic, 
analgesic and antibiotic drugs. Several therapeutic important molecules prepared through 
mannich reaction have received more attention in recent years.4-6 Mannich bases have 
gained important because of their technological application in polymer chemistry,7 
especially as paints and surface active agent and it also exhibits complexation 
characteristic with many transition metal ions. 
 
SYNTHETIC ASPECT 
Different methods have been cited to synthesize some new mannich bases by 
several coworkers using various interesting substrates. 





















 37 % reflux
(1)
 

















3. A. Katsifis et al.10 have prepared mannich bases (3) of imidazo[1,2-a]pyridine. 
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4. Several new aminobenzylated mannich bases (4) have been prepared by 
condensing reaction between heterocyclic secondary amines, aldehydes and 





















Over the years there has been much controversy about the mechanism of the 





The mechanism of the Mannich reaction starts with the formation of an iminium 
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Because the reaction takes place under acidic conditions, the compound with the 
carbonyl functional group (in this case a ketone) can tautomerize to the enol form, after 









































































A wide variety of pharmacological properties and industrial applications have 










10. Antifungal21  
11. Anticancer22 
 
 Several therapeutic important molecules containing heterocyclic secondary 
amines are well known. For example, Manafflazineis a famous antiarthritic agent and 
Minorine is used as antidepressant. 
S. K. Sridhar23 have synthesized some new mannich bases and screened for anti-
inflammatory activity. A. R. Bhat et al.24 have reported mannich bases of quinoxaline and 
evaluated for their antibacterial, antifungal and antitubercular activities. 
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P. Y. Shirodkar and M. M. Vartak25 have studied the antitubercular activity of 












Craig J. Roxburgh et al.26 have reported mannich bases and tested them for local 









Christina Reichwald et al.27 have synthesized mannich bases of 9-tert-butyl-2-
phenylethinylpaullone (7) from 1,3-diarylpropenones using aromatic aldehydes and 







Yan Huang, et al.28 have synthesized some mannich bases and reported as 
anticancer agent. Ya. L. Garazd et al.29 have prepared mannich bases of hydroxyl- 
coumarines (8) which posses various biological activities. 
 
Studies on chemical… 










Work done from our laboratory  
K. S. Nimavat30 have synthesized some new aminobenzylated mannich bases 
and reported as an antimicrobial agent. Study of mannich bases of 4-amino-3-
mercapto-5-pyridin-3'-yl-[1,2,4]-triazole reported by T. K. Dave.31 Green chemistry 
approach to potentially bioactive aminobenzylated mannich bases through active 
hydrogen compounds reported by S. L. Vasoya.32 
 Thus with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological screening, we have 
under taken the synthesis of several mannich bases which has been described as under. 
 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-(4-     
FLUOROPHENYL)-6-METHYL-3-(N,N-DIALKYLAMINE-4-YL 












Studies on chemical… 
Mannich base derivatives…                                                                                            114 
SECTION-I 




Encouraged by earlier positive result in respect of mannich bases compounds have 
gained lot of interest in last several year due to their biological, physiological and 
industrial importance, based on extensive studies of pharmacological properties, it was 
thought of interest to synthesize some new mannich bases by condensation of 2-(4-
fluorophenyl)-6-methylimidazo[1,2-a]pyridine with different secondary amines and 

















The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Shimadzu-10AT. Elemental 
analysis of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned.  
 
[A] Synthesis of 2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-a]pyridine. 
See Part-B, Part-I, Section-I, Experimental section [A]. 
 
[B] General procedure for the preparation of 2-(4-Fluorophenyl)-6-methyl-3-
(N,N-dialkylamine-4-ylmethyl)imidazo[1,2-a]pyridines. 
To a solution of 2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridine (2.26 g, 
0.01 mol), formaldehyde (0.3 g, 0.01 mol) and different secondary amine (0.01 mol) in 
methanol (20 ml) was added and the reaction mixture was refluxed with stirring in the 
presence of 1-2 drop concentrated HCl. After completion of reaction (monitoring by 
TLC) cool the reaction mass and add ice cold water and extracted with ethyl acetate. The 
organic layer was washed with water (2 x 10 ml) and dried with Na2SO4, solvent was 
removed in vacuo and the resulting crude product was pure by colum chromatography to 
give the analytical pure compound. The physical constants of the product are recorded in 
Table-5a. 
 
[C] Biological evaluation of 2-(4-Fluorophenyl)-6-methyl-3-(N,N-dialkylamine-4-
ylmethyl)imidazo[1,2-a]pyridines.  
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
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337.43 73 0.44 
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ANALYTICAL DATA 
2-(4-Fluorophenyl)-6-methyl-3-(morpholin-4-ylmethyl)imidazo[1,2-a]pyridine (5a). 
mp 183-185 °C; Purity by HPLC: 98 %; IR (KBr): 3114 (Ar, C-H str), 3009 (C-H str), 
2956 (C-H str), 1657 (C=N str), 1576 (Ar, C=C str), 1460 (Ar, C=C str), 1345 (C-H str), 
1214 (C-N str), 1158 (C-F), 841 (C-H, o.p. ban) cm-1; 1H NMR (400 MHz, CDCl3): δ 
ppm 2.29 (s, 3H, CH3), 2.38-2.40 (t, J=4.44 Hz, 4H, 2CH2), 3.58-3.61 (t, J=4.52 Hz, 4H, 
2CH2), 3.81 (s, 2H, CH2), 6.98-7.01 (m, 1H, ArH), 7.03-7.08 (m, 2H, ArH), 7.45-7.47 (d, 
J=9.12 Hz, 1H, ArH), 7.68-7.72 (m, 2H, ArH), 8.06 (s, 1H, ArH). 13C NMR (100 MHz, 
CDCl3): δ ppm 18.55, 51.94, 53.18, 66.97, 115.29, 115.50, 116.55, 121.68, 122.66, 
127.93, 130.43, 130.51, 130.66, 130.69, 144.08, 144.18, 161.29, 163.74; MS: m/z = 326 
[M+1]+; Anal. Calcd for C19H20FN3O: C, 70.13; H, 6.20; N, 12.91. Found: C, 69.83; H, 
6.13; N, 12.76%. 
 
N-Ethyl-N-{[2-(4-fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]methyl} 
ethanamine (5b). mp 147-148 °C; Purity by HPLC: 99 %; IR (KBr): 3072, 2980, 2862, 
1603, 1554, 1434, 1456, 1119, 1035, 820 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 0.99-
1.03 (t, J=7.08 Hz, 6H, CH3), 2.29 (s, 3H, CH3), 2.46-2.52 (q, J=7.2 Hz, 4H, CH2), 3.98 
(s, 2H, CH2), 6.99-7.02 (m, 1H, ArH), 7.06-7.09 (m, 2H, ArH), 7.52-7.54 (d, J=10.56 Hz, 
1H, ArH), 7.74-7.78 (m, 2H, ArH), 8.10 (s, 1H, ArH). 13C NMR (100 MHz, CDCl3): δ 
ppm 13.11, 21.68, 50.93, 52.18, 115.50, 115.80, 116.75, 122.20, 123.30, 128.50, 130.80, 
130.99, 131.06, 131.10, 144.48, 144.60, 161.80, 164.12; MS: m/z = 311 [M]+; Anal. 
Calcd for C19H22FN3: C, 73.28; H, 7.12; N, 13.49. Found: C, 72.53; H, 7.03; N, 13.33%. 
 
2-(4-Fluorophenyl)-6-methyl-3-[(4-phenylpiperazin-1-yl)methyl]imidazo[1,2-a] 
pyridine (5c). mp 192-194 °C; IR (KBr): 3080, 2968, 2835, 1599, 1574, 1481, 1463, 
1138, 1043, 850 cm-1; MS: m/z = 400 [M]+; Anal. Calcd for C25H25FN4: C, 74.97; H, 
6.29; N, 13.99. Found: C, 74.21; H, 6.07; N, 13.75%. 
 
2-(4-Fluorophenyl)-6-methyl-3-(piperidin-1-ylmethyl)imidazo[1,2-a]pyridine (5d). 
mp 198-199 °C; IR (KBr): 3076, 2961, 2863, 1645, 1542, 1453, 1378, 1143, 1037, 832 
cm-1; MS: m/z = 325 [M+2]+; Anal. Calcd for C20H22FN3: C, 74.28; H, 6.86; N, 12.99. 
Found: C, 74.05; H, 6.77; N, 12.71%. 
 
N-{[2-(4-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]methyl}-N-isopropyl 
propan-2-amine (5e). mp 124-126 °C; IR (KBr): 3084, 2967, 2857, 1605, 1559, 1462, 
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1376, 1134, 1054, 845 cm-1; MS: m/z = 339 [M]+; Anal. Calcd for C21H26FN3: C, 74.30; 
H, 7.72; N, 12.38. Found: C, 73.17; H, 7.59; N, 12.26%. 
 
2-(4-Fluorophenyl)-6-methyl-3-[(4-ethylpiperazin-1-yl)methyl]imidazo[1,2-a] 
pyridine (5f). mp 223-224 °C; IR (KBr): 3078, 2959, 2886, 1612, 1551, 1487, 1389, 
1144, 1046, 848 cm-1; MS: m/z = 353 [M+1]+; Anal. Calcd for C21H25FN4: C, 71.56; H, 
7.15; N, 15.90. Found: C, 71.34; H, 7.01; N, 15.72%. 
 
2-(4-Fluorophenyl)-6-methyl-3-[(4-methylpiperazin-1-yl)methyl]imidazo[1,2-a] 
pyridine (5g). mp 173-175 °C; IR (KBr): 3097, 2956, 2872, 1611, 1534, 1456, 1451, 
1129, 1034, 865 cm-1; MS: m/z = 339 [M+1]+; Anal. Calcd for C20H23FN4: C, 70.98; H, 
6.85; N, 16.56. Found: C, 70.83; H, 6.74; N, 16.47%. 
 
2-(4-Fluorophenyl)-6-methyl-3-(pyrrolidin-1-ylmethyl)imidazo[1,2-a]pyridine (5h). 
mp 144-145 °C; IR (KBr): 3082, 2954, 2868, 1614, 1559, 1446, 1471, 1139, 1043, 870 
cm-1; MS: m/z = 309 [M]+; Anal. Calcd for C19H20FN3: C, 73.76; H, 6.52; N, 13.58. 
Found: C, 72.32; H, 6.29; N, 13.45%. 
 
2-(4-Fluorophenyl)-6-methyl-3-[(2-methylpiperidin-1-yl)methyl]imidazo[1,2-a] 
pyridine (5i). mp 153-155 °C; IR (KBr): 3046, 2964, 2834, 1621, 1558, 1448, 1356, 
1126, 1048, 837 cm-1; MS: m/z = 337 [M]+; Anal. Calcd for C21H24FN3: C, 74.75; H, 
7.17; N, 12.45. Found: C, 74.37; H, 7.05; N, 12.36%. 
 
2-(4-Fluorophenyl)-6-methyl-3-[(4-methylpiperidin-1-yl)methyl]imidazo[1,2-a] 
pyridine (5j). mp 134-136 °C; IR (KBr): 3089, 2956, 2885, 1625, 1545, 1446, 1426, 
1146, 1023, 842 cm-1; MS: m/z = 337 [M]+; Anal. Calcd for C21H24FN3: C, 74.75; H, 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
HPLC of compound 5a  
Column :  Phenomenex Luna C8 (2) (250mm x 4.6mm i.d., 5 μm particle size) 
Mobile phase :  Acetonitrile – 0.02M phosphate buffer pH 3.5 (60: 40, v/v). 
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Mass spectrum of compound 5a 
 
 















M. Wt. = 400.49
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1H NMR spectrum of compound 5a 
 
 








Studies on chemical… 
Mannich base derivatives…                                                                                            122 
1H NMR spectrum of compound 5b 
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13C NMR spectrum of compound 5a 
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Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
5a 100 100 250 250 200 1000 1000 
5b 100 200 100 500 250 500 250 
5c 250 250 250 125 500 1000 1000 
5d 200 250 125 500 1000 250 500 
5e 250 200 500 500 500 1000 1000 
5f 100 62.5 100 200 500 200 500 
5g 200 500 62.5 250 250 500 250 
5h 500 250 500 200 200 200 500 
5i 200 500 200 100 500 200 250 
5j 500 200 250 250 500 250 200 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
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INTRODUCTION     
Bis imidazo[1,2-a]pyridine (1) is an aromatic heterocyclic organic compound 
having one carbon atom is common with attached two imidazo[1,2-a]pyridine ring 
system. Hence they are interesting target to be prepared to our research on medicinally 








As evident from the literature in recent years a significant portion of research 
work in heterocyclic chemistry has been devoted to bis imidazo[1,2-a]pyridine containing 
different aryl, alkyl and heteroaryl groups as substituent. 
 
SYNTHETIC ASPECT 
Various methods for the preparation of dimer have been cited in literature, some 
of the methods are as under. 
1. R. Zhang et al.1 synthesized bis-imidazo[1,2-a]pyridinylmethanes from imidazole 


















2. Y. Sumalatha and coworkers2 have been reported bis-imidazo[1,2-a]pyridine 
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3. J. C. Teulade and coworkers3 have been reported some bis imidazo[1,2-a]azines 















4. K. Asakawa et al.4 have synthesized bis benzimidazoles and reported alternative 



































6. W. Oi and coworkers6 synthesized phenyl bis indole and reported selective 













7. G. V. Ramin, et al.7 synthesized bis(indolyl)methanes in water and also 
synthesized di-, tri-, and tetra(bis-indolyl)methanes under thermal conditions 
catalyzed by oxalic acid dehydrate.  
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8. G. K. P. Surya and coworkers8 reported microwave assisted synthesis of 








A wide variety of pharmacological properties and industrial applications have 
been encountered with several dimer such as, 
1. Antimicrobial9 
2. Antiinflammatory10 
3. Anti cancer11 
4. Analgesic12 
5. Antifungal13  
6. Anti-HIV14 
7. Anti protozoal15 
8. Anti malarial16 
9. Cytotoxic Activity17 
10. Anti tumor18 
 
N. P. Kozyreva and coworkers19 synthesized co-bis benzo[g]quinol (2) derivatives 
and tested their antimalarial activity. A. O. Abdelhamid et al.20 have reported 
antimicrobial evaluation of synthesized compound. L. S. Fernandez et al.21 have reported 
synthesis of bis-indole alkaloids from flindersia species and their antimalarial activity.    
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R. Rohini et al.22 have synthesized bis-indolo[1,2-c]quinazolines (3) and evaluated 
them for antimicrobial studies. L. Dassonneville et al.23 reported plant alkaloid 










K. Oh et al.24 have reported synthesis and antimicrobial activities of halogenated 
bis(hydroxyphenyl)methanes (4). C. S. Reddy and coworkers25 have synthesized and 
evaluated novel bis[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles as potent antimicrobial agents. 
S. M. Sondhi and coworkers26 reported biological activity of novel bis Schiff bases, bis 








K. V. Sashidhara et al.27 have synthesized and reported antihyperlipidemic activity 
of novel coumarin bisindole (5) derivatives. X. H. Gu et al.28 synthesized and reported 
biological activities of bis(3-indolyl)thiazoles, analogs of marine bis(indole)alkaloid 
nortopsentins. G. A. Youngdale et al. synthesized 5-substituted 2,3-bis(p-methoxyphenyl) 
indoles and reported their antiinflammatory activity. C. Praveen and coworkers29 have 
documented bis(indolyl)methanes and evaluated of their antimicrobial and antioxidant 
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activity. S. Ahn and coworkers30 reported a novel bis-indole destabilize microtubules and 










M. A. Ismail and coworkers31 have reported synthesis and antiprotozoal activity of 
novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-
a]pyridines. M. R. Jacobs et al.32 have prepared some novel bis-indole agents active 
against multidrug resistant acinetobacter baumannii. B. B. Dey et al.33 reported a 
coumarin dimer directly linked without any bridge. R. Rohini and coworkers34 presented 
bis-6-arylbenzimidazo[1,2-c]quinazolines, a new class of antimicrobial agents.  
Thus with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological screening, we have 
under taken the synthesis of several dimer which has been described as under. 
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SECTION-I 




Bis imidazo[1,2-a]pyridine derivatives are important intermediates in organic 
synthesis, especially in the synthesis of biologically active and medicinally useful agents. 
For instance, they are widely used in the synthesis of cyclin-dependent kinases (CDK) 
inhibitors, sleep inducers, anticonvulsant agents, etc. The synthesis of some new 





















The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Shimadzu-10AT. Elemental 
analysis of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned. 
 
[A] Synthesis of 2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-a]pyridine. 
See Part-B, Part-I, Section-I, Experimental section [A]. 
 
[B] General procedure for the preparation of 2-(4-Fluorophenyl)-3-((2-(4-
fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl)(aryl)methyl)-6-methyl 
H-imidazo[1,2-a]pyridines.  
To a mixture of 2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridine (4.52 g, 
0.02 mol) and aromatic aldehydes (0.01 mol) in acetic acid (4 ml), sodium acetate 1.0 g 
was added and refluxed for 24 hour (monitoring by TLC). After cooling to room 
temperature, the reaction mixture was diluted with water and made basic with saturated 
sodium carbonate solution. The solution was extracted with dichloromethane and the 
organic layer was dried over anhydrous Na2SO4. After the solvent was evaporated, the 
residue was chromatographed on silica gel (eluent 6 : 4 = E.A. : Hexane) to give 
analytical pure products. The physical constants of the product are recorded in Table-6a. 
 
[C] Biological evaluation of 2-(4-Fluorophenyl)-3-((2-(4-fluorophenyl)-6-methylH 
-imidazo[1,2-a]pyridin-3-yl)(aryl)methyl)-6-methylH-imidazo[1,2-a] 
pyridines. 
 Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
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ANALYTICAL DATA 
2-(4-Fluorophenyl)-3-((2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl)(p-
tolyl)methyl)-6-methylH-imidazo[1,2-a]pyridine (6a). mp 161-163 °C; Purity by 
HPLC: 87 %; IR (KBr): 3069 (Ar, C-H str), 2920 (C-H str), 2862 (C-H str), 1616 (C=N 
str), 1534 (Ar, C=C str), 1464 (Ar, C=C str), 1340 (C-H ban), 1179 (C-N str), 1089 (C-F), 
845 (C-H o.p. ban) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 2.34 (s, 3H, CH3), 2.44 (s, 
6H, CH3), 5.34 (s, 1H, CH), 7.03-7.05 (m, 2H, ArH), 7.08-7.16 (m, 4H, ArH), 7.20-7.24 
(m, 2H, ArH), 7.51-7.52 (d, J=7.16 Hz, 2H, ArH), 7.53-7.55 (d, J=9.2 Hz, 2H, ArH), 
7.72-7.80 (m, 4H, ArH), 7.88-7.92 (m, 2H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 
18.15, 21.74, 40.49, 107.54, 115.57, 115.78, 116.63, 122.41, 123.36, 127.59, 127.67, 
128.31, 129.76, 144.30, 144.55, 163.91; MS: m/z = 554 [M]+; Anal. Calcd for 
C36H28F2N4: C, 77.96; H, 5.09; N, 10.10. Found: C, 76.31; H, 4.87; N, 10.03%. 
 
2-(4-Fluorophenyl)-3-((2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl) 
(thiophen-2-yl)methyl)-6-methylH-imidazo[1,2-a]pyridine (6b). mp 192-193 °C; 
Purity by HPLC: 84 %; IR (KBr): 3068, 2977, 2823, 1600, 1576, 1435, 1377, 1150, 1067, 
840 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 2.52 (s, 6H, CH3), 5.41 (s, 1H, CH), 6.54-
6.56 (m, 1H, ArH), 6.81-6.87 (m, 1H, ArH), 6.99-7.07 (m, 1H, ArH), 7.11-7.18 (m, 4H, 
ArH), 7.19-7.23 (m, 2H, ArH), 7.31-7.58 (m, 2H, ArH), 7.74-7.79 (m, 4H, ArH), 7.95-
7.99 (m, 2H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 19.17, 41.12, 104.24, 111.40, 
111.78, 112.90, 126.67, 126.80, 127.44, 129.04, 139.64, 140.46, 146.93, 147.14, 164.33; 
MS: m/z = 546 [M]+; Anal. Calcd for C33H24F2N4S: C, 72.51; H, 4.43; N, 10.25. Found: 
C, 71.78; H, 4.38; N, 10.07%. 
 
2-(4-Fluorophenyl)-3-((2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl) 
(phenyl)methyl)-6-methylH-imidazo[1,2-a]pyridine (6c). mp 175-177 °C; IR (KBr): 
3099, 2975, 2849, 1599, 1557, 1439, 1366, 1134, 1054, 842 cm-1; MS: m/z = 541 [M+1]+; 




nitrophenyl)methyl)-6-methylH-imidazo[1,2-a]pyridine (6d). mp 209-211 °C; IR 
(KBr): 3081, 2966, 2843, 1634, 1584, 1446, 1366, 1240, 1138, 1031 cm-1; MS: m/z = 585 
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[M]+; Anal. Calcd for C35H25F2N5O2: C, 71.79; H, 4.30; N, 11.96. Found: C, 70.70; H, 
4.17; N, 11.79%. 
 
3-((4-Chlorophenyl)(2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl) 
methyl)-2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridine (6e). mp 203-204 °C; 
IR (KBr): 3087, 2988, 2867, 1616, 1558, 1467, 1346, 1135, 1021, 720 cm-1; MS: m/z = 
577 [M+2]+; Anal. Calcd for C35H25ClF2N4: C, 73.10; H, 4.38; N, 9.74. Found: C, 72.18; 
H, 4.26; N, 9.66%. 
 
4-(Bis(2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl)methyl) 
benzenamine (6f). mp 185-187 °C; IR (KBr): 3490, 3073, 2973, 2864, 1611, 1567, 1454, 
1386, 1138, 1036 cm-1; MS: m/z = 556 [M+1]+; Anal. Calcd for C35H27F2N5: C, 75.66; H, 
4.90; N, 12.60. Found: C, 75.18; H, 4.77; N, 12.43%. 
 
2-(4-Fluorophenyl)-3-((4-fluorophenyl)(2-(4-fluorophenyl)-6-methylH-imidazo[1,2- 
a]pyridin-3-yl)methyl)-6-methylH-imidazo[1,2-a]pyridine (6g). mp 232-234 °C; IR 
(KBr): 3090, 2961, 2853, 1614, 1546, 1467, 1369, 1129, 1043 cm-1; MS: m/z = 558 [M]+; 




methyl)-2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridine (6h). mp 226-228 °C; 
IR (KBr): 3088, 2976, 2858, 1606, 1568, 1434, 1374, 1144, 1046, 840 cm-1; MS: m/z = 
619 [M]+; Anal. Calcd for C35H25BrF2N4: C, 67.86; H, 4.07; N, 9.04. Found: C, 67.33; H, 
3.83; N, 9.00%. 
 
2-(4-Fluorophenyl)-3-((2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl)(4-
methoxyphenyl)methyl)-6-methylH-imidazo[1,2-a]pyridine (6i). mp 157-159 °C; IR 
(KBr): 3087, 2973, 2851, 1600, 1587, 1446, 1379, 1099, 1063 cm-1; MS: m/z = 570 [M]+; 




mp 177-178 °C; IR (KBr): 3440, 3082, 2946, 2864, 1609, 1579, 1446, 1378, 1149, 1081 
cm-1; MS: m/z = 557 [M+1]+; Anal. Calcd for C35H26F2N4O: C, 75.52; H, 4.71; N, 10.07. 
Found: C, 74.67; H, 4.47; N, 9.84%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
HPLC of compound 6a  
Column :  YMC C-8 (4.6 x 150 mm, 5 µm particle size)   
Mobile phase :  Acetonitrile – 0.02M phosphate buffer pH 3.5 (60: 40, v/v). 
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Mass spectrum of compound 6b 
 
 

















M. Wt. = 546.63
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1H NMR spectrum of compound 6a 
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1H NMR spectrum of compound 6b 
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13C NMR spectrum of compound 6a 
 
 


















Studies on chemical… 
Bis imidazo[1,2-a]pyridine derivatives…                                                                       142 






Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
6a 250 500 100 500 250 500 1000 
6b 200 100 250 100 200 1000 500 
6c 50 100 250 100 1000 500 250 
6d 250 250 500 500 500 250 500 
6e 200 250 100 250 250 500 250 
6f 500 250 200 100 200 250 250 
6g 100 500 125 500 500 1000 500 
6h 250 100 500 200 1000 500 250 
6i 250 200 200 200 500 200 500 
6j 125 100 250 100 250 250 250 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
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 INTRODUCTION 
Thiophene-2-carbaldehyde (1) is an aromatic heterocyclic compound consisting of 
four carbon atoms and one sulfur atom in a five-membered ring. Thiophene was 
discovered by Viktor Meyer in 1883 as a contaminant in benzene.1 Related to thiophene 
are benzothiophene and dibenzothiophene, containing the thiophene ring fused with one 
and two benzene rings. 
It was observed that isatin forms a blue dye if it is mixed with sulfuric acid and 
crude benzene. Victor Meyer was able to isolate the substance responsible for this 






Thiophenes are important class of heterocyclic compounds and are recurring 
building blocks in organic chemistry with applications in pharmaceuticals. The benzene 
ring of a biologically active compound may often be replaced by a thiophene without loss 
of activity.3 Thiophene and its derivatives occur in petroleum, sometimes in 
concentrations up to 1-3%. The thiophenic content of liquids from oil and coal is removed 
via the hydrodesulfurization (HDS) process. 
 
SYNTHETIC ASPECT 
Various methods for the preparation of thiophene derivatives have been cited in 
literature, some of the methods are as under. 
1. Y. Kopylov and coworkers4 synthesized thiophene via butane, (methyldi-



















12 hrs , RT  
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3. Moon, Jeongju and coworkers6 synthesized thiophenes and 2,2'-bithiophene using 
sodium butoxide and cyclohexenone, palladium as catalyst. 
 






4. N. T. Berberova et al.7 have synthesized thiophenes and thiophene-2-thiol via 
dichloro methane and hydrogen sulphide at 20-25 °C. 
 




5. A. R. Katritzky et al.8 have synthesized thiophenes from 2,5-dimethylthiophene 






6. E. N. Deryagina and coworkers9 synthesized thiophenes from 2-chlorothiophene 
and ethyne.  
 





Over recent years there has been an increasing interest in the chemistry of 
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9. Diuretic23 
10. Insecticidal24 
11. Antipsychotic25  
12. Anticancer26,27 
 
S. F. Mohmad28 have prepared {[4-(thiophen-2-yl)-3,4,5,6-tetrahydrobenzo 









Gautam Panda29 have prepared 2-{phenyl[4-(2-phenylethoxy)phenyl] methyl} 







M. S. Malamas and coworkers30 have synthesized novel thiophene derivatives 
inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. S. S. 
Perez et al.31 developed 5-substituted thiophene derivatives with dual action at 5-HT1A 
serotonin receptors and serotonin transporter as a new class of antidepressants. Synthesis 
and serotonergic activity of thiophene-4-piperazine derivatives as novel antagonists for 
the vascular 5-HT1B receptor has been achieved by G. P. Moloney and group.32 
Derivatives of benzo[b]thiophene are also available as drug, some of them are 
shown as under:  
Studies on chemical… 
























Work done from our laboratory  
V. V. Kachhadia et al.33 have synthesized 6-carbethoxy-5-aryl-3-[p-(3'-chloro-2'-
benzo[b]thiophenoylamino)phenyl]-2-cyclohexenones derivatives bearing benzo[b] 
thiophene nucleus and reported their antitubercular and antimicrobial activity.34 
S. L. Vasoya et al.35 reported facile synthesis of some new azetidinones and acetyl 
oxadiazoles as a potent biological active agent, he also synthesized thiosemicarbazides 
and 1,3,4-thiadiazoles as potent antitubercular and antimicrobial agents,36 moreover he 
has reported thiosemicarbazide and 1,2,4-triazoles heterocycles as a potent antitubercular 
and antimicrobial agents37 bearing benzo[b]thiophene nucleus.  
Prior art search reveals that thiophene derivatives are proved to be potent 
biodynamic agents, for their various methods of synthesis and different biological 
activities, synthesis of thiophene derivatives have been undertaken in order to achieving 
superior therapeutic agents. This can be summarized in the following sections as under.  
 
 
STUDIES ON THIOPHENE DERIVATIVES 
 
PART-I: STUDIES ON PYRAZOLINE DERIVATIVES       








Studies on chemical… 
Thiophene derivatives…                                                                                                  149 
REFERENCES 
1. V. Meyer, Berichte der Deutschen chemischen Gesellschaft, 16, 1465-1478 (1883).   
2. W. C. Sumpter, Chemical Reviews, 34(3), 393-434 (1944).   
3. D. Lednicer, Wiley Interscience, 14, 187 (1999). 
4. A. Y. Kopylov, R. R. Sadykov, K. G. Sadikov, A. M. Mazgarov, A. V. Vildanov, Z. R. 
Ismagilov, S. R. Khairulin, S. A. Yashnik, Uglevodorodnogo Syrya Neftekhimiya, 48(2), 
112-117 (2008).   
5. L. Xinmiao, W. Xinliang, L. Renhua, X. Qing, X. Xingya, Z. Feifang, Faming Zhuanli 
Shenqing Gongkai Shuomingshu, CN  101544548, pp 13 (2009).   
6. M. Jeongju, L. Sunwo, J. Organomet. Chem., 694(3), 473-477 (2009). 
7. N. T. Berberova, V. A. Khokhlov, E. V. Shinkar, Y. Y. Alekhina, Astrakhanskii 
Gosudarstvennyi Tekhnicheskii Universitet, RU  2340609, pp 4 (2008). 
8. A. R. Katritzky, M. Balasubramanian, S. Michael, Energy & Fuels, 6(4), 431-438 (1992). 
9. E. N. Deryagina, E. N. Sukhomazova, E. P. Levamova, M. G. Voronkov, Russia.    
Zhurnal Organicheskoi Khimii, 31(6), 925-927 (1995).  
10. H. S. Tholappanavara, K. M. Mahadevan, H. N. Harishkumar, P. Basavaraj, N. Gadada, 
Phosphorus, Sulfur and Silicon and the Related Elements, 184(7), 1866-1879 (2009). 
11. R. Shakru, N. J. P. Subhashini, K. S. Kumar, Shivaraj, Journal of Chemical and 
Pharmaceutical Research, 2(1), 38-46 (2010).  
12. T. H. Suresha, K. M. Mahadevan, H. N. Harishkumar, P. Basavaraj, N. Gadada,   
Phosphorus, Sulfur and Silicon and the Related Elements, 184(7), 1866-1879 (2009). 
13. R. Kulandasamy, A. A. Vasudeva, J. P. Stables, Eur. J. Med. Chem., 44(11), 4376-4384 
(2009). 
14. K. P. Kumar, J. V. Rao, K. Mukkanti, M. B. Raju, K. A. Khan, Journal of Pharmacy 
Research, 3(5), 1021-1024 (2010).  
15. S. Bondock, W. Fadaly, M. A. Metwally, Eur. J. Med. Chem., 45(9), 3692-3701 (2010).      
16. W. J. Moree, F. Jovic, T. Coon, J. Yu, B. Li, F. C. Tucci, D. Marinkovic, R. S. Gross, S. 
Malany, M. J. Bradbury, Bioorg. Med. Chem. Lett., 20(7), 2316-2320 (2010).    
17. R. P. Alexander, B. Stuart, D. C. Brookings, J. A. Brown, C. Sacha, F. C. Pollard, PCT 
Int. Appl. WO 2010001126,  pp 46 (2010).   
18. B. Ramesh, B. Someswara Rao, E-Journal of Chemistry, 7(2), 433-436 (2010).  
19. M. A. El-Sherbeny, A. A. Abdel-Aziz, M. A. Ahmed, Eur. J. Med. Chem., 45(2),  689-
697 (2010).   
20. K. Wilson, D. A. Gabriela, H. Andrew, K. Kaleen, M. Michelle, Z. Anna, PCT Int. Appl. 
WO  2010005841, pp 74 (2010).   
21. M. R. Leivers, R. Lauchli, PCT Int. Appl. WO 2010006096, pp 236 (2010). 
Studies on chemical… 
Thiophene derivatives…                                                                                                  150 
22. A. E. Rashad, A. H. Shamroukh, R. E. Abdel-Megeid, A. Mostafa, R. El-Shesheny, A. 
Kandeil, M. A. Ali, K. Banert, Eur. J. Med. Chem., 45(11), 5251-5257 (2010).   
23. S. M. Abdel Wahab, N. M El-Fiki, M. A. Amin, S. F. Mostafa, Bulletin of the Faculty of 
Pharmacy (Cairo University), 45(1), 93-104 (2007).   
24. J. W. Hull, D. R. Romer, T. J. Adaway, D. E. Podhorez, Organic Process Research & 
Development, 13(6),  1125-1129 (2009). 
25. O. Tadaaki, I. Nobuaki, Y. Hiroshi, M. Shin, M. Motoyuki, M. Jun, PCT Int. Appl. WO 
2009128537, pp 46. (2009).      
26. S. Fletcher, E. P. Keaney, C. G. Cummings, M. A. Blaskovich, M. A. Hast, M. P. Glenn, 
S. Y. Chang, C. J. Bucher, R. J. Floyd, W. P. Katt, J. Med. Chem., 53(19), 6867-6888 
(2010).      
27. M. A. Shaaban, M. M. Ghorab, H. I. Heiba, M. M. Kamel, N. H. Zaher, M. I. Mostafa, 
Arch. Pharm., 343(7), 404-410 (2010).    
28. S. F. Mohmad, H. K. Thabet, E. E. Mustafa, M. M Abdalla, S. H. Shafik, World J. 
Chemistry, 4(2), 100-108, (2009). 
29. G. Panda, M. K. Parai, A. K. Shrivastava, V. Chaturvedi, Y. K. Manju, S. Sinha, Indian J. 
Chem.: B, 48(B), 1121-1127, (2009). 
30. M. S. Malamas, J. Sredy, C. Moxham, A. Katz, F. O. Adebayo, D. R. Sawicki, J. R. 
Taylor, J. Med. Chem., 43(7), 1293-1310 (2000).   
31. S. S. Perez, E. J. Martinez, B. Lasheras, R. J. Del, A.Monge, Pharmazie, 59(7), 499-501 
(2004). 
32. G. P. Moloney, A. Garavelas, G. R. Martin, M. Maxwell, R. C. Glen, Eur. J. Med. Chem., 
39(4), 305-321 (2004).   
33. V. V. Kachhadia, K. H. Popat, K. S. Nimavat, H. S. Joshi, J. Indian Chem. Soc., 81(8), 
694-695 (2004). 
34. V. V. Kachhadia, M. R. Patel, H. S. Joshi, J. Serb. Chem. Soc., 70(2), 153-161 (2005). 
35. S. L. Vasoya, M. R. Patel, S. V. Dobaria, H. S. Joshi, Indian J. Chem.: B, 44(2), 405-409 
(2005). 
36. S. L. Vasoya, D. J. Paghdar, P. T. Chovatia, H. S. Joshi, J. Sci., I. R. Iran, 16(1), 33-36, 
(2005). 




Part – C 
(Part – I) 
 







Studies on chemical… 
Pyrazole derivatives…                                                                                                                          151 
INTRODUCTION  
The chemistry of pyrazoles has been reviewed by Jarobe in 1967. Pyrazoles have 
attracted attention of medicinal chemists for both with regard to heterocyclic chemistry 
and the pharmacological activities associated with them. Pyrazole have been studied 
extensively because of ready accessibility, diverse chemical reactivity, broad spectrum of 
biological activity1 and varieties of industrial applications.2 
Pyrazole has three possible tautomeric structures. But 2-pyrazole (1) consist a 







As evident from the literature in recent years a significant portion of research 
work in heterocyclic chemistry has been devoted to pyrazoles containing different alkyl, 
aryl and heteroaryl groups as substituents. 
 
SYNTHETIC ASPECT 
Different methods are available from the literature for the preparation of 2-
pyrazole derivatives. The most common procedure for the synthesis of 2-pyrazoles is the 


















ALTERNATIVE SYNTHETIC ROUTES FOR IMPROVED YIELD, SHORTER 
REACTION TIME AND MILDER CONDITIONS TO SYNTHESIZE NEW ANALOGS 
Solid-Phase Synthesis 
L. L. De3 reported cellulose beads as a new versatile solid support for microwave-
assisted synthesis of pyrazole and isoxazole libraries. 
 
 































Wang resin supported solid-phase synthesis of pyrazoledicarboxylic acid 


















Similarly many other solid phase synthesis of pyrazole motif were reported using 
different solid support such as (4-formyl-3-methyoxyphenoxy)methylpolystyrene (FMP) 
resin,5 polymer-supported vinylsulfone,6 Kenner ‘safety catch’ resin,7 KOH powder.8 
 
Liquid-Phase Synthesis 
X. L. Ren and coworkers9 have synthesized pyrazole derivatives using liquid 













V. N. Pathak and coworkers10,11 reported 3,5-diarylpyrazole synthesis using phase 
transfer catalyst. Heterocyclic pyrazole was synthesized by the W. C. Shen and 
coworkers.12 
 
Microwave Assisted Synthesis 
Microwave irradiation and solvent-free conditions was reported for the rapid and 
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New "Green" approaches to the synthesis of pyrazole derivatives were reported by 























Similarly in literature there are number of the reports for the use of microwave 
irradiation for the rapid synthesis, high yield or towards the green approach of the 
reaction under solvent free conditions. Some of them are reported as below. 
S. S. Chauhan15 derived pyrazoles from diaryl 1,3-diketones, I. Rinski and 
coworkers16 prepared 1,3-dipolar cycloaddition of diazo compounds to acetylene 
derivatives, M. A. P. Martins et al.17 reported regiospecific synthesis of 5-trifluoromethyl-
4,5-dihydropyrazoles, H. S. P. Rao18 derived microwave mediated combinatorial 
synthesis, S. A. Swelam19 derived pyrazole under dry media, M. A. P. Martins and 
coworkers20 reported regiospecific synthesis of pyrazole, B. R. Rao and 
coworkers21synthesis pyrazole by use of p-toluenesulphonic acid and S. Katade et al.22 
reported microwave synthesis of pyrazole.           
P. Kumar et al.23 have synthesized of pyrazole chalcones under solvent free 
condition at room temperature. X. H. Liu et al.24 reported novel dihydropyrazole 
derivatives linked with 4H-chromene.  
 
Catalysts 
 Many of the organic chemists prefered to use catalyst to get the desire product 
with high yield and within sort reaction time and to convert the reaction condition from 
drastic to easily operational with some specific catalyst.  
R. Ali reported stereoselective synthesis of N-vinyl pyrazoles in solvent-free 
conditions using dipotassium hydrogen phosphate powder.25 Zinc-catalyzed syntheses of 




OH 5 mol % Zn(OTf)2 N
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In literature there are number of the catalysts are used for the synthesis of pyrazole 
system like Conjugate base,27 Iodine(III),28 Hafnium chloride,29 Tungstophosphoric 





The following mechanism seems to be operable for pyrazoline by the 




















































( I ) ( II )
( III ) ( IV )( V )  
 
Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl 
system (I) forms species (II), in which the negative charge is mainly accommodated by 
the electronegative oxygen atom.  
Proton transfer from the nitrogen to oxygen produces an intermediate and which 
simultaneously ketonises to ketoamine (III). Another intramolecular nucleophillic attack 
by the primary amino group of ketoamine on its carbonyl carbon followed by proton 
transfer from nitrogen to oxygen leads ultimately to hydroxyl amine (IV). The later with a 





From the literature survey, it was revealed that 2-pyrazolines are better therapeutic 
agents. They possess valuable bioactivities like 
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1.  Antiinflammatory37,38 
2. Analgesic39,40 
3.  Bactericidal41 
4.  Fungicidal42,43 
5.  Anticonvulsant44 
6.  Pesticidal45,46 
7.  Antidepressant47 
8.  Antiamoebic48 
9. Insecticidal49 
10. Antineoplastic50,51 
11.  Herbicidal52 
 
M. K. Shivnanda and coworkers53 have prepared pyrazolines and reported their 
antibacterial activity. Antimicrobial activity of pyrazoline derivatives (2) have been 
reported by K. N. Sharma et al.54 J. Almstead et al.55 have prepared pyrazolines as 










M. Q. Fan et al.57 have synthesized pyrazolines and tested their antidepressant 
activity. Antiamoebic activity of pyrazoline derivatives have been reported by Asha 
Budakoti and coworkers.58 J. H. Ahn et al.59 have reported cyanopyrazoline (3) 
derivatives as potent antidiabetic agents. T. S. Jeong et al.60 have synthesized some novel 
3,5-diaryl pyrazolines (4) as human acyl-Co A: cholesterol acyltransferase inhibitors. G. 
Ucar et al.61 reported pyrazolines as cholinstearase andselective monoamine oxidase-B 
inhibitiors for the treatment of parkinson and alzheimer’s diseases. M. N. Nasr et al.62 
have reported the synthesis of newer arylthiazolylpyrazoline derivatives as 
antiinflammatory agents. M. A. Berghot et al.63 have prepared for convergent synthesis 
and antibacterial activity of pyrazole and pyrazoline derivatives of diazepam. 
 















(3) (4)  
 
N. Gokhan et al.64 have synthesized the pyrazoline derivatives of 1-N-substituted 
thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines (5) as MAO inhibitors. Mohammad 
Abid and Amir Azam65 have synthesized 1-N-substituted cyclized pyrazoline of 
thiosemicarbazones (6) and reported as antiamoebic agents. V. Malhotra et al.66 have 
documented new pyrazolines as a cardiovascular agents. Antidepressant activity of 













(5) (6)  
 
Abd El-Galil E. Amr et al.68 have synthesized some new 3-substituted 
androstano[17,16-c]-5,2-aryl-pyrazolines and reported their antiandrogenic activity. B. 
Bizzarri et al.69 have reported in vitro selective anti-helicobacter pylori activity (7) of 
pyrazoline derivatives. Bhat and coworkers70 reported cytotoxic properties of pyrazoline 
derivatives. Antibacterial activity of pyrazoline derivatives have been reported by A. M. 
Gandhi and coworkers.71 S. Bondock et al.72 have synthesized pyrazolines as 
antimicrobial agents. S. P. Hiremath et al.73 have synthesized pyrazolines as analgesic, 
antiinflammatory and antimicrobial agents. Rajendra Prasad et al.74 have synthesized 
some 1,3,5-triphenyl-2-pyrazolines (8) and 3-(2"-hydroxynaphthalen-1"-yl)-1,5-diphenyl-
2-pyrazolines and reported as antidepressant agents. J. H. M. Lange et al.75 synthesized 
and reported 3,4-diaryl pyrazoline analogues as potent and selective CB1 cannabinoid 
receptor antagonists. N. T. Ha Duong et al.76 have been synthesized some pyrazole 
derivatives as inhibitors for the active sites of human liver cytochromes P450 of the 2C 
subfamily. 
 












(7) (8)  
 
X. Zhang and coworkers77 have been prepared pyrazoline derivatives (9) as potent 
selective androgen receptor modulators. R. M. Mohareb and coworkers78 have been 
























F. Chimenti and coworkers79 have been demonstrated a novel series of 1-acetyl-3-
(4-hydroxy and 2,4-dihydroxyphenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole derivatives 
(11) and investigated for the ability to selectively inhibit the activity of monoamine 
oxidase (MAO). Y. R. Huang et al.80 have been prepared a series of 4-alkyl-1,3,5-
triarylpyrazoles (12) as ligands for the estrogen receptor. C. D. Cox et al.81 and J. R. 
Goodell et al.82 have been reported separately some pyrazoline derivatives as anti-obesity 
agents by antagonizing CB1 receptors and therapeutic candidates for parkinson’s disease. 
A series of 3-(4-fluorophenyl)-4,5-dihydro-N-[4-(trifluoromethyl)-phenyl]-4-[5-
(trifluoromethyl)-2-pyridyl]-1H-pyrazole-1-carboxamide has been synthesized and 
studied for their potent foliar activity against both lepidoptera and orthoptera insects by P. 
K. Leonard et al.83 Bruce G. Szczepankiewicz et al.84 have been prepared some pyrazole 











(11) (12)  
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Guniz Kuchkguzel et al.85 have synthesized pyrazolines as a antimicrobial and 
anticonvulsant agents. P. Singh and coworkers86 have prepared pyrazolines as a antitumor 
agent.  
 
Work done from our laboratory  
K. S. Nimavat87 have synthesized 1-substituted 3-aryl-5-(3’-bromophenyl)-
pyrazolines which shows anticancer, antitubercular and antimicrobial activity. D. H. 
Vyas88 reported synthesis and biological activity of some pyrazoline derivatives bearing 
3,5-dibromo-4-methoxybenzaldehyde nucleus.  
P. T. Chovatia89 have been reported 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-
pyrazole derivatives as a antitubercular and antimicrobial agent. T. K. Dave90 reported 
synthesis, antitubercular and antimicrobial evaluation of pyrazole derivatives bearing 
nicotinic acid nucleus. Synthesis of some pyrazolo[3,4-d]pyrimidines and thiazolo[4,5-
d]pyrimidines and evaluation of their antimicrobial activities with derivatives of urea and 
thiourea was reported by J. D. Akbari et al.91,92 
Literature survey reveals that the compounds bearing pyrazole moiety possess 
potential drug activity. Looking to the diversified biological activities we have 
synthesized some pyrazole derivatives in order to achieving better therapeutic agents. 
These studies are described in following section. 
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SECTION-I 




Pyrazole derivatives represent one of the most active class of compound having a 
wide spectrum of biological activities. Looking to the interesting properties of pyrazoles 
it was considered worthwhile to synthesize a series of pyrazoles for obtaining biologically 
potent agent which were prepared by reacting chalcones with 1H-indole-2-

































The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Shimadzu-10AT. Elemental 
analysis of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned. 
 
[A] Preparation of 1H-Indole-2-carbohydrazide. 
See Part-A, Part-II, Section-I, Experimental section [A]. 
 
[B] Preparation of 1-Phenyl-3-(thiophen-2-yl)prop-2-en-1-ones.  
These were prepared by condensation of thiophen-2-carbaldehyde and substituted 
acetophenones in the presence of sodium hydroxide as described by N. M. Rateb93 and 
Dalla Via,94 M. M. Hania.95  
 
[C] Preparation of 3-Phenyl-1-(thiophen-2-yl)prop-2-en-1-one. 
These were prepared by condensation of 2-acetylthiophen and substituted aryl 
aldehyde in the presence of sodium hydroxide as described by B. Ramesh et al.96  
 
[D] General procedure for the preparation of 1H-Indol-2-yl[3-aryl/thiophene-5-
(thiophen/aryl-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]methanones. 
1H-Indole-2-carbohydrazide (1.75 g, 0.01 mol) was charged into 250 ml round 
bottom flask. 10 ml of glacial acetic acid was added to dissolve it. Then add substituted 
chalcones (0.01 mol). The reaction mixture was refluxed on an oil bath for 12 hour. The 
progress and the completion of the reaction were monitoring by TLC. After the 
completion of reaction the mixture was poured onto crushed ice to give solid product. 
Finally, it was purified by colum chromatography. (eluent 3 : 7 = E.A. : Hexane) 
Similarly other compounds were prepared. The physical constants of the product are 
recorded in Table-7a. 
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[E] Biological evaluation of 1H-Indol-2-yl[3-aryl/thiophene-5-(thiophen/aryl-2-
yl)-4,5-dihydro-1H-pyrazol-1-yl]methanones. 
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
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methanone (7a). mp 145-147 °C; Purity by HPLC: 94 %; IR (KBr): 3365 (N-H str), 3090 
(Ar, C-H str), 2955 (C-H str), 2908 (C-H str), 1637 (amide, C=O str), 1610 (C=N str), 
1556 (Ar, C=C str), 1475 (Ar, C=C str), 1184 (N-N str), 1014 (C-N str), 796 (C-Cl) cm-1; 
1H NMR (400 MHz, CDCl3): δ ppm 3.20-3.26 (dd, J=3.92&17.60 Hz, 1H, CH), 3.70-
3.76 (dd, J=8.64&16.60 Hz, 1H, CH), 5.82-5.86 (dd, J=3.80&11.40 Hz, 1H, CH), 6.87-
6.98 (m, 2H, ArH), 7.02-7.16 (m, 2H, ArH), 7.19-7.25 (m, 1H, ArH), 7.27-7.44 (m, 4H, 
ArH), 7.45-7.57 (m, 2H, ArH), 7.59-7.68 (m, 1H, ArH), 9.61 (s, 1H, NH). 13C NMR (100 
MHz, CDCl3): δ ppm 41.97, 55.43, 115.84, 124.70, 124.83, 125.08, 126.87, 127.86, 
127.95, 128.15, 128.40, 129.07, 129.31, 129.74, 130.37, 130.45, 131.10, 137.01, 159.23, 
164.58; MS: m/z = 405 [M]+; Anal. Calcd for C22H16ClN3OS: C, 65.10; H, 3.97; N, 10.35. 
Found: C, 65.03; H, 3.85; N, 10.21%. 
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1H-Indol-2-yl[5-(4-methylphenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] 
methanone (7b). mp 231-232 °C; Purity by HPLC: 97 %; IR (KBr): 3580, 3072, 2956, 
2842, 1682, 1600, 1582, 1438, 1146, 1021, 840 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 
2.44 (s, 3H, CH3), 3.36-3.42 (dd, J=4&17.6 Hz, 1H, CH), 3.73-3.80 (dd, J=11.36&17.6 
Hz, 1H, CH), 6.12-6.16 (dd, J=3.96&11.32 Hz, 1H, CH), 7.08-7.19 (m, 4H, ArH), 7.27-
7.33 (m, 4H, ArH), 7.39-7.46 (m, 1H, ArH), 7.63-7.68 (m, 1H, ArH), 7.74-7.76 (d, 
J=8.16 Hz, 2H, ArH), 9.79 (s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ ppm 21.64, 
21.72, 41.13, 56.65, 110.44, 111.85, 120.39, 120.82, 122.63, 124.84, 124.94, 126.87, 
126.91, 128.26, 128.35, 128.58, 128.65, 129.36, 129.47, 129.72, 131.97, 136.87, 141.54, 
143.95, 156.00, 158.42; MS: m/z = 387 [M+2]+; Anal. Calcd for C23H19N3OS: C, 71.66; 
H, 4.97; N, 10.90. Found: C, 71.49; H, 4.82; N, 10.86%. 
 
1H-Indol-2-yl[5-phenyl-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]methanone 
(7c). mp 169-171 °C; IR (KBr): 3561, 3071, 2941, 2862, 1683, 1621, 1558, 1423, 1175, 
1012 cm-1; MS: m/z = 371 [M]+; Anal. Calcd for C22H17N3OS: C, 71.14; H, 4.61; N, 
11.31. Found: C, 71.02; H, 4.55; N, 11.27%. 
 
[5-(4-Fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7d). mp 133-135 °C; IR (KBr): 3568, 3086, 2955, 2872, 1681, 1593, 1588, 
1568, 1422, 1156, 1113, 820 cm-1; MS: m/z = 390 [M+1]+; Anal. Calcd for C22H16FN3OS: 
C, 67.85; H, 4.14; N, 10.79. Found: C, 67.76; H, 4.10; N, 10.69%. 
 
[5-(2,4-Dichlorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-
yl)methanone (7e). mp 128-130 °C; IR (KBr): 3572, 3071, 2936, 2858, 1686, 1598, 
1570, 1554, 1429, 1188, 1050, 720 cm-1; MS: m/z = 441 [M+1]+; Anal. Calcd for 
C22H15Cl2N3OS: C, 60.01; H, 3.43; N, 9.54. Found: C, 59.87; H, 3.31; N, 9.42%. 
 
[5-(3-Aminophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7f). mp 205-207 °C; IR (KBr): 3564, 3068, 2976, 2828, 1684, 1613, 1579, 
1546, 1438, 1164, 1049, 780 cm-1; MS: m/z = 386 [M]+; Anal. Calcd for C22H18N4OS: C, 
68.37; H, 4.69; N, 14.50. Found: C, 67.35; H, 4.47; N, 14.37%. 
 
[5-(4-Aminophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7g). mp 117-119 °C; IR (KBr): 3579, 3079, 2982, 2837, 1690, 1609, 1559, 
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1558, 1429, 1186, 1020, 740 cm-1; MS: m/z = 386 [M]+; Anal. Calcd for C22H18N4OS: C, 
68.37; H, 4.69; N, 14.50. Found: C, 67.89; H, 4.52; N, 14.35%. 
 
1H-Indol-2-yl[5-(3-nitrophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] 
methanone (7h). mp 123-124 °C; IR (KBr): 3548, 3062, 2979, 2842, 1689, 1606, 1576, 
1568, 1434, 1164, 1024, 780 cm-1; MS: m/z = 417 [M+1]+; Anal. Calcd for C22H16N4O3S: 
C, 63.45; H, 3.87; N, 13.45. Found: C, 62.35; H, 3.75; N, 13.38%. 
 
[5-(4-Bromophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7i). mp 165-167 °C; IR (KBr): 3589, 3079, 2961, 2853, 1682, 1600, 1575, 
1562, 1451, 1174, 1029, 855 cm-1; MS: m/z = 450 [M]+; Anal. Calcd for C22H16BrN3OS: 
C, 58.67; H, 3.58; N, 9.33. Found: C, 57.82; H, 3.22; N, 9.27%. 
 
[5-(4-Hydroxyphenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7j). mp 159-161 °C; IR (KBr): 3588, 3086, 2946, 2866, 1686, 1611, 1588, 
1573, 1466, 1166, 1010, 842 cm-1; MS: m/z = 388 [M]+; Anal. Calcd for C22H17N3O2S: C, 
68.20; H, 4.42; N, 10.85. Found: C, 67.88; H, 4.29; N, 10.68%. 
 
[3-(4-Fluorophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7k). mp 135-136 °C; IR (KBr): 3481, 3108, 2923, 2871, 1697, 1590, 1578, 
1554, 1492, 1135, 1028, 830 cm-1; MS: m/z = 391 [M+1]+; Anal. Calcd for C22H16FN3OS: 
C, 67.85; H, 4.14; N, 10.79. Found: C, 66.88; H, 4.07; N, 10.57%. 
 
[3-(3-Chlorophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7l). mp 212-214 °C; IR (KBr): 3395, 3051, 2987, 2856, 1704, 1617, 1608, 
1585, 1578, 1089, 1042, 740 cm-1; MS: m/z = 406 [M+1]+; Anal. Calcd for 
C22H16ClN3OS: C, 65.10; H, 3.97; N, 10.35. Found: C, 64.87; H, 3.71; N, 10.23%. 
 
1H-Indol-2-yl[3-(4-methylphenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] 
methanone (7m). mp 187-189 °C; IR (KBr): 3371, 3108, 3005, 2915, 1689, 1584, 1578, 
1566, 1463, 1183, 1018, 870 cm-1; MS: m/z = 385 [M]+; Anal. Calcd for C23H19N3OS: C, 
71.66; H, 4.97; N, 10.90. Found: C, 70.49; H, 4.73; N, 10.56%. 
 
1H-Indol-2-yl[3-phenyl-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]methanone 
(7n). mp 232-234 °C; IR (KBr): 3386, 3067, 2984, 2859, 1694, 1605, 1591, 1595, 1483, 
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1204, 1023, 845 cm-1; MS: m/z = 371 [M]+; Anal. Calcd for C22H17N3OS: C, 71.14; H, 
4.61; N, 11.31. Found: C, 70.66; H, 4.28; N, 11.07%. 
 
[3-(4-Chlorophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7o). mp 221-223 °C; IR (KBr): 3365, 3048, 2988, 2851, 1682, 1571, 1580, 
1536, 1456, 1134, 1093, 856 cm-1; MS: m/z = 406 [M+1]+; Anal. Calcd for 
C22H16ClN3OS: C, 65.10; H, 3.97; N, 10.35. Found: C, 64.59; H, 3.61; N, 10.09%. 
 
1H-Indol-2-yl[3-(2-nitrophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] 
methanone (7p). mp 213-214 °C; IR (KBr): 3486, 3152, 3046, 2846, 1676, 1651, 1612, 
1551, 1491, 1008, 1281, 750 cm-1; MS: m/z = 416 [M]+; Anal. Calcd for C22H16N4O3S: C, 
63.45; H, 3.87; N, 13.45. Found: C, 62.38; H, 3.53; N, 13.39%. 
 
1H-Indol-2-yl[3-(4-nitrophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-
yl]methanone (7q). mp 188-189 °C; IR (KBr): 3386, 3089, 3018, 2914, 1689, 1586, 
1579, 1523, 1469, 1087, 1028, 825 cm-1; MS: m/z = 416 [M]+; Anal. Calcd for 
C22H16N4O3S: C, 63.45; H, 3.87; N, 13.45. Found: C, 62.87; H, 3.59; N, 13.19%. 
 
[3-(4-Aminophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7r). mp 195-197 °C; IR (KBr): 3519, 3076, 2964, 2852, 1704, 1609, 1581, 
1568, 1542, 1159, 1065, 810 cm-1; MS: m/z = 386 [M]+; Anal. Calcd for C22H18N4OS: C, 
68.37; H, 4.69; N, 14.50. Found: C, 67.78; H, 4.53; N, 14.28%. 
 
[3-(4-Bromophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl](1H-indol-2-yl) 
methanone (7s). mp 173-175 °C; IR (KBr): 3312, 3128, 3064, 2883, 1683, 1615, 1586, 
1542 1453, 1286, 1003, 737 cm-1; MS: m/z = 451 [M+1]+; Anal. Calcd for 
C22H16BrN3OS: C, 58.67; H, 3.58; N, 9.33. Found: C, 57.63; H, 3.27; N, 9.05%. 
 
1H-Indol-2-yl[3-(4-methoxyphenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] 
methanone (7t). mp 104-106 °C; IR (KBr): 3428, 3162, 3029, 2918, 1711, 1610, 1591, 
1542, 1508, 1162, 1063, 760 cm-1; MS: m/z = 401 [M]+; Anal. Calcd for C23H19N3O2S: C, 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
HPLC of compound 7a  
Column :  YMC C-8 (4.6 x 150 mm, 5 µm particle size) 
Mobile phase :  Acetonitrile – 0.02M phosphate buffer pH 3.5 (60: 40, v/v). 
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Mass spectrum of compound 7a  
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1H NMR spectrum of compound 7a 
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1H NMR spectrum of compound 7b 
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13C NMR spectrum of compound 7a 
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Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
7a 250 200 100 62.5 200 200 200 
7b 500 100 100 200 250 500 250 
7c 200 500 200 250 500 250 500 
7d 100 200 100 200 1000 1000 1000 
7e 200 250 62.5 100 200 >1000 250 
7f 200 125 250 500 1000 500 500 
7g 500 100 250 200 500 1000 200 
7h 125 250 500 250 200 200 250 
7i 100 200 200 100 250 200 250 
7j 50 100 125 200 500 500 500 
7k 250 200 100 250 1000 250 250 
7l 100 250 250 500 500 1000 500 
7m 250 200 500 200 250 500 250 
7n 250 500 250 100 1000 500 >1000 
7o 500 100 200 125 250 200 200 
7p 250 500 100 200 200 250 500 
7q 100 100 500 250 250 500 1000 
7r 250 500 500 200 500 200 500 
7s 100 250 200 500 >1000 200 200 
7t 500 200 100 250 200 1000 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
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INTRODUCTION 
Pyrimidine is the most important member of all the diazines as this ring system 
occurs widely in living organisms. Purines, uric acid, barbituric acid, anti-malarial and 
anti-bacterial agents also contain the pyrimidine ring. The chemistry of pyrimidine has 
been widely studied. Pyrimidine was first isolated by Gabriel and Colman in 1899. Since 
pyrimidine is symmetrical about the line passing C-2 and C-5, the positions C-4 and C-6 
are equivalent and so N-1 and N-3 are equivalent. Depicts the five possible isomeric 
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Different methods have been cited to synthesize some new pyrimidines by several 
coworkers using various interesting substrates. 
1. N. A. Hassan et al.1 have synthesized various differently substituted 






















2. Ladda and Bhatnagar2 have described an efficient nimentowski synthesis of novel 
















X = O/S 
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3. X. S. Wang3 have synthesized 5,7-diarylpyrido[2,3-d]pyrimidine derivatives using 
KF-alumina catalyst. 
 


































There are several strategies to prepare fused pyrimidine ring systems. The 
construction of a pyrimidine ring system from 2-amino five / six membered heterocyclic 
derivatives follows the typical reaction sequence. One of the most popular approaches to 
construct the pyrimidine ring is via the synthesis of substituted ureas and thio ureas. In a 
first step, the amino group of the any heterocycle moiety is converted into a urea by 
treatment with an isocyanate5, potassium cyanate hydrochloride6, or chlorosulfonyl 
isocyanate7 and into a thiourea by reaction with an isothiocyanate8, or thiophosgene and 
an amine9. The resulting ureas and thioureas readily undergo an intramolecular 
cyclization upon treatment with bases or acids to afford the fused pyrimidine ring 


















A : Hetrocycle ring
X = CO2Et or CN
Y = O or S X = CN, Z = NH
X = CO2Et, Z = O  
 
The synthesis of substituted pyrimidin-4-ones is well studied and can be 
categorized into four groups according to the functional groups on the fused heterocyclic 
moiety and the structures of the intermediates. 
(1) Substituted pyrimidinones can be prepared via cyclization of diamides 
intermediates, which are generated from aminocarbamoylbenzopyrans by reaction 
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with acylating agents such as orthoesters,10 acid anhydrides and acid chlorides,11 
formic acid12 and diethyl oxalate.13  
(2) Alternatively, the synthesis of substituted pyrimidinones can be achieved from 
aminoalkoxycarbonylbenzopyrans. Amidine intermediates, formed by the reaction 
of the fused heterocyclic compound with amides,14 nitrites under acidic 
conditions,15 orthoesters and amines,16 undergo an intramolecular cyclization to 
afford chromeno pyrimidinones.  
(3) A third procedure is based on the recyclization of substituted oxazinones, which 
are generated by reaction of aminocarboxylic acids or esters with acid chlorides or 
orthoesters.17 The recyclization proceeds through the diamide intermediate which 
is generated upon treatment with amines.18 
(4) Aminocyanoheterocyclic compounds also serve as valuable starting materials for 
the synthesis of substituted pyrimidinones. Initially, the oxazinimine intermediates 
are generated by the acylation of the amino group and then recyclization in the 



























A : Hitrocyclic ring
























A : Hetrocyclic ring
X = H or R'
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THERAPEUTIC IMPORTANCE 
A wide variety of pharmacological properties and industrial applications have 












Alloxan (1) is known for its diabetogenic action in a number of animals30 Uracil 























(1) Alloxan (2) Uracili (3) Thymine (4) Cytisine  
 
Calcium ion plays a vital role in a large number of cellular processes, including 
excitation-contraction and stimulus-secretion.31,32 The regulation of the intracellular 
concentration of this ion makes possible the control of such Ca2+ dependent processes. 
One means of accomplishing this is by the use of agents known as calcium channel 
antagonists, which inhibit the movement of calcium through certain membrane channel.33-
35 K. S. Atwal36 prepared the 2-heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-
pyrimidinecarboxylic acid esters (5), which lack the potential C3 symmetry of 
dihydropyridine calcium channel blockers. The solid-state structure of dihydropyrimidine 
analogue (6) shows that these compounds can adopt a molecular conformation which is 
similar to the reported conformation of dihydropyridine calcium channel blockers. 
 


















(5) (6)  
 
S. Sarac and coworkers37,38 have synthesized 4-arlyl-3,4-dihydropyrimidin-2(1H)-
one/thione derivatives. The calcium channel blocker activities of all compounds 
performed on isolated rat ileum. Product (7), 2-nitrophenyl derivative and (8), 2-

















N. Dhanapalan and coworkers39 have synthesized dihydropyrimidinones and 
describe compound (9) have a high binding affinity (Ki = 0.2nM) for a1a receptor and 


















2-Thiouracil (10c) and its alkyl analogue, thiobarbital (10e) are effective drugs 
against hyperthyroidism. Propylthiouracil (10d) is used as a drug for hyperthyroidism 
with minimum side effects.40  











(10c) = R = R1 = R2 = H, X = S, 2-Thiouracil 
(10d) = R = R1 = H, R2 = C3H7, X = S, Propylthiouracil 
(10e) = R = R1 = C2H5, R2 = O, X = S, Thiobarbital  
 
These drugs have the ability of ridding the body of parasitic worms. Pyrantel 
pamoate (11) is a depolarizing neuromuscular blocking agent that causes spastic paralysis 









Work done from our laboratory   
P. D. Zalavadiya42 have synthesized some new dihydropyrimidines by iodine 
catalyst at ambient temperature and reported as antitubercular agent. Pyrazolo[3,4-d] 
pyrimidines and thiazolo[4,5-d]pyrimidines reported by J. D. Akbari et al.43 Green 
chemistry approach to synthesis of some new trifluoromethyl containing 
tetrahydropyrimidines was reported by H. S. Joshi et al.44 
 Thus with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological screening, we have 
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SECTION-I 




Much interest has been focused around pyrido[2,3-d]pyrimidines derivatives 
because of their wide variety of pharmacological properties and industrial application. In 
view of these finding and achieve to better drug potency, we have synthesized 2-Methyl-
5-aryl/thiophen-7-(thiophen/aryl-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-ones by the 
cyclocondensation of 2-amino-6-aryl/thiophene-4-(thiophene/aryl-2-yl)pyridine-3-







































The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Shimadzu-10AT. Elemental 
analysis of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned.  
 
[A] Preparation of 1-Aryl/thiophen-3-(thiophen/aryl-2-yl)prop-2-en-1-one. 
See Part-C, Part-I, Section-I, Experimental section [B] and [C]. 
 
[B] Preparation of 2-Methyl-4-aryl/thiophen-6-(thiophen/aryl-2-yl)pyridine-3-
carbonitrile.45   
A mixture of chalcone (0.01 mol), malononitrile (0.66 g, 0.01 mol) and 
ammonium acetate (6.16 g, 0.08 mol) in a methanol (20 ml) was refluxed for 4-6 hour. 
After the completion of reaction (monitoring by TLC), cool the content, the solid 
separated was filtered and wash with methanol and dried to give analytical pure product. 
 
[C] General procedure for the preparation of 2-Methyl-5-aryl/thiophen-7-
(thiophen/aryl-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-ones. 
A mixture of an appropriate 2-methyl-4-aryl/thiophen-6-(thiophen/aryl-2-yl) 
pyridine-3-carbonitrile (0.01 mol) and acetic acid (20 ml) was stirred under reflux for 12-
14 hour in the presence of catalytic amount of concentrated H2SO4. The reaction mixture 
was allowed to cool to room temperature and was poured into ice cold water. The solid 
thus formed was collected by filtration, washed with chloroform (20 ml) and the resulting 
crude product was crystallized from methanol to give the analytical pure compound. The 
physical constants of the product are recorded in Table-8a. 
 
[D] Biological evaluation of 2-Methyl-5-aryl/thiophen-7-(thiophen/aryl-2-yl) 
pyrido[2,3-d]pyrimidin-4(3H)-ones.  
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-8b. 
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Cl C18H12ClN3OS 353.82 75 0.36 
8b ″ CH3 C19H15N3OS 333.40 82 0.48 
8c ″ C18H13N3OS 319.38 69 0.41 


































































































































































(8a). mp 179-181 °C; Purity by HPLC: 95 %; IR (KBr): 3390 (N-H str), 3028 (Ar, C-H 
str), 2935 (C-H str), 2853 (C-H str), 1687 (amide, C=O str), 1611 (C=N str), 1532 (Ar, 
C=C str), 1446 (Ar, C=C str), 1015 (C-N str), 820 (C-H, o.p. ban) cm-1; 1H NMR (400 
MHz, DMSO-d6): δ ppm 2.51 (s, 3H, CH3), 7.29-7.31 (m, 1H, ArH), 7.46-7.49 (m, 1H, 
ArH), 7.59-7.60 (d, J=4.4 Hz, 1H, ArH), 7.69-7.70 (d, J=5.20 Hz, 2H, ArH), 7.83-7.84 
(d, J=4.40 Hz, 2H, ArH), 7.98 (s, 1H, NH), 8.18-8.20 (d, J=9.08 Hz, 1H, ArH). 13C NMR 
(100 MHz, DMSO-d6): δ ppm 21.08, 111.23, 112.70, 114.62, 117.92, 123.23, 124.00, 
128.80, 130.20, 132.10, 135.45, 139.12, 141.14, 154.16, 159.78, 165.18; MS: m/z = 355 
[M+1]+; Anal. Calcd for C18H12ClN3OS: C, 61.10; H, 3.42; N, 11.88. Found: C, 60.31; H, 
3.27; N, 11.65%. 
 
2-Methyl-7-(4-methylphenyl)-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8b). mp 186-188 °C; Purity by HPLC: 96 %; IR (KBr): 3365, 3068, 2979, 2851, 1694, 
1611, 1571, 1567, 1456, 1078, 840 cm-1; 1H NMR (400 MHz, DMSO-d6): δ ppm 2.44 (s, 
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3H, CH3), 2.79 (s, 3H, CH3), 7.16-7.18 (m, 1H, ArH), 7.33-7.37 (m, 1H, ArH), 7.46-7.47 
(d, J=2.92 Hz, 1H, ArH), 7.59-7.62 (d, J=4.64 Hz, 2H, ArH), 7.74-7.75 (d, J=3.88 Hz, 
1H, ArH), 7.88 (s, 1H, NH), 8.05-8.07 (d, J=8.20 Hz, 2H, ArH). 13C NMR (100 MHz, 
DMSO-d6): δ ppm 19.96, 21.03, 110.20, 117.72, 121.10, 123.45, 127.02, 127.41, 129.40, 
130.28, 131.78, 135.20, 138.64, 141.76, 153.20, 158.21, 163.28; MS: m/z = 334 [M+1]+; 
Anal. Calcd for C19H15N3OS: C, 68.45; H, 4.53; N, 12.60. Found: C, 68.07; H, 4.41; N, 
12.29%. 
 
2-Methyl-7-phenyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one (8c). mp 141-
142 °C; IR (KBr): 3433, 3078, 2976, 2858, 1692, 1612, 1569, 1567, 1443, 1013 cm-1; 
MS: m/z = 319 [M]+; Anal. Calcd for C18H13N3OS: C, 67.69; H, 4.10; N, 13.16. Found: C, 
66.38; H, 4.04; N, 13.00%. 
 
7-(4-Fluorophenyl)-2-methyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8d). mp 159-161 °C; IR (KBr): 3459, 3086, 2966, 2846, 1693, 1611, 1572, 1564, 1450, 
1061, 825 cm-1; MS: m/z = 339 [M+2]+; Anal. Calcd for C18H12FN3OS: C, 64.08; H, 3.59; 
N, 12.46. Found: C, 63.66; H, 3.49; N, 12.34%. 
 
7-(2,4-Dichlorophenyl)-2-methyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8e). mp 239-241 °C; IR (KBr): 3464, 3068, 2969, 2884, 1693, 1613, 1586, 1570, 1454, 
1029, 747 cm-1; MS: m/z = 389 [M+1]+; Anal. Calcd for C18H11Cl2N3OS: C, 55.68; H, 
2.86; N, 10.82. Found: C, 55.13; H, 2.48; N, 10.72%. 
 
7-(3-Aminophenyl)-2-methyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8f). mp 167-169 °C; IR (KBr): 3497, 3068, 2946, 2860, 1697, 1609, 1576, 1568, 1446, 
1007, 759 cm-1; MS: m/z = 334 [M]+; Anal. Calcd for C18H14N4OS: C, 64.65; H, 4.22; N, 
16.75. Found: C, 64.31; H, 4.10; N, 16.35%. 
 
7-(4-Aminophenyl)-2-methyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8g). mp 118-120 °C; IR (KBr): 3455, 3055, 2968, 2835, 1691, 1618, 1561, 1569, 1453, 
1081, 867 cm-1; MS: m/z = 334 [M]+; Anal. Calcd for C18H14N4OS: C, 64.65; H, 4.22; N, 
16.75. Found: C, 64.18; H, 4.08; N, 16.43%. 
 
2-Methyl-7-(3-nitrophenyl)-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one (8h). 
mp 243-245 °C; IR (KBr): 3500, 3097, 2976, 2849, 1695, 1600, 1565, 1562, 1435, 1071, 
Studies on chemical… 
Pyrimidine derivatives…                                                                                                                     189 
738 cm-1; MS: m/z = 365 [M+1]+; Anal. Calcd for C18H12N4O3S: C, 59.33; H, 3.32; N, 
15.38. Found: C, 58.91; H, 3.13; N, 15.06%. 
 
7-(4-Bromophenyl)-2-methyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8i). mp 144-146 °C; IR (KBr): 3468, 3079, 2991, 2864, 1690, 1605, 1573, 1565, 1459, 
1034, 690 cm-1; MS: m/z = 399 [M]+; Anal. Calcd for C18H12BrN3OS: C, 54.28; H, 3.04; 
N, 10.55. Found: C, 53.65; H, 2.84; N, 10.36%. 
 
7-(4-Hydroxyphenyl)-2-methyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8j). mp 188-189 °C; IR (KBr): 3488, 3086, 2946, 2868, 1697, 1612, 1581, 1580, 1456, 
1022, 857 cm-1; MS: m/z = 335 [M]+; Anal. Calcd for C18H13N3O2S: C, 64.46; H, 3.91; N, 
12.53. Found: C, 63.54; H, 3.77; N, 12.31%. 
  
5-(4-Fluorophenyl)-2-methyl-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8k). mp 201-203 °C; IR (KBr): 3364, 3060, 3045, 2891, 1693, 1585, 1558, 1545, 1463, 
1075, 851 cm-1; MS: m/z = 338 [M+1]+; Anal. Calcd for C18H12FN3OS: C, 64.08; H, 3.59; 
N, 12.46. Found: C, 63.18; H, 3.41; N, 12.26%. 
 
5-(3-Chlorophenyl)-2-methyl-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8l). mp 256-258 °C; IR (KBr): 3468, 3051, 3008, 2960, 1698, 1618, 1604, 1578, 1471, 
1078, 770 cm-1; MS: m/z = 355 [M]+; Anal. Calcd for C18H12ClN3OS: C, 61.10; H, 3.42; 
N, 11.88. Found: C, 60.58; H, 3.17; N, 11.53%. 
 
2-Methyl-5-(4-methylphenyl)-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8m). mp 294-296 °C; IR (KBr): 3504, 3145, 2978, 2861, 1712, 1645, 1618, 1563, 1545, 
1063, 841 cm-1; MS: m/z = 333 [M]+; Anal. Calcd for C19H15N3OS: C, 68.45; H, 4.53; N, 
12.60. Found: C, 67.57; H, 4.30; N, 12.49%. 
 
2-Methyl-5-phenyl-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one (8n). mp 216-
217 °C; IR (KBr): 3341, 3029, 2983, 2866, 1709, 1595, 1583, 1568, 1478, 1018 cm-1; 
MS: m/z = 319 [M]+; Anal. Calcd for C18H13N3OS: C, 67.69; H, 4.10; N, 13.16. Found: C, 
67.09; H, 3.97; N, 13.05%. 
 
5-(4-Chlorophenyl)-2-methyl-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8o). mp 176-177 °C; IR (KBr): 3309, 3151, 2998, 2905, 1691, 1683, 1578, 1543, 1518, 
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1023, 854 cm-1; MS: m/z = 354 [M+1]+; Anal. Calcd for C18H12ClN3OS: C, 61.10; H, 
3.42; N, 11.88. Found: C, 60.48; H, 3.21; N, 11.49%. 
 
2-Methyl-5-(2-nitrophenyl)-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one (8p). 
mp 181-183 °C; IR (KBr): 3290, 3043, 3023, 2818, 1890, 1609, 1590, 1579, 1449, 1065, 
720 cm-1; MS: m/z = 364 [M]+; Anal. Calcd for C18H12N4O3S: C, 59.33; H, 3.32; N, 
15.38. Found: C, 58.86; H, 3.18; N, 15.09%. 
 
2-Methyl-5-(4-nitrophenyl)-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one (8q). 
mp 166-167 °C; IR (KBr): 3351, 3031, 3015, 2957, 1876, 1602, 1589, 1578, 1479, 1043, 
710 cm-1; MS: m/z = 364 [M]+; Anal. Calcd for C18H12N4O3S: C, 59.33; H, 3.32; N, 
15.38. Found: C, 56.87; H, 3.15; N, 15.27%. 
 
5-(4-Aminophenyl)-2-methyl-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8r). mp 210-211 °C; IR (KBr): 3481, 3147, 2969, 2884, 1707, 1578, 1563, 1533, 1469, 
1021, 844 cm-1; MS: m/z = 334 [M]+; Anal. Calcd for C18H14N4OS: C, 64.65; H, 4.22; N, 
16.75. Found: C, 64.01; H, 4.16; N, 16.58%. 
 
5-(4-Bromophenyl)-2-methyl-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8s). mp 248-250 °C; IR (KBr): 3501, 3170, 3046, 2930, 1681, 1619, 1615, 1578, 1503, 
1056, 866 cm-1; MS: m/z = 399 [M+1]+; Anal. Calcd for C18H12BrN3OS: C, 54.28; H, 
3.04; N, 10.55. Found: C, 53.81; H, 2.91; N, 10.41%. 
 
5-(3-Methoxyphenyl)-2-methyl-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 
(8t). mp 229-230 °C; IR (KBr): 3349, 3093, 29636, 2847, 1680, 1620, 1595, 1583, 1493, 
1037, 767 cm-1; MS: m/z = 349 [M]+; Anal. Calcd for C19H15N3O2S: C, 65.31; H, 4.33; N, 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
HPLC of compound 8a  
Column :  YMC C-8 (4.6 x 150 mm, 5 µm particle size) 
Mobile phase :  Acetonitrile – 0.02M phosphate buffer pH 3.5 (60: 40, v/v). 
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Mass spectrum of compound 8a 
 
 

















M. Wt. = 353.82
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1H NMR spectrum of compound 8a 
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1H NMR spectrum of compound 8b 
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13C NMR spectrum of compound 8a 
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Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
8a 50 500 250 100 500 250 250 
8b 100 250 100 250 1000 200 500 
8c 125 62.5 100 200 250 500 >1000 
8d 250 200 500 200 200 1000 500 
8e 500 100 200 250 1000 500 1000 
8f 200 100 500 200 500 >1000 500 
8g 200 100 250 100 200 250 250 
8h 100 200 200 250 500 200 500 
8i 250 200 250 200 500 500 200 
8j 500 250 500 500 >1000 500 500 
8k 200 500 62.5 100 500 200 250 
8l 250 100 100 500 1000 200 500 
8m 100 200 500 250 500 250 500 
8n 500 125 500 200 250 500 1000 
8o 250 100 100 200 200 500 500 
8p 200 250 200 250 >1000 >1000 500 
8q 500 250 250 200 500 200 250 
8r 500 200 100 250 200 250 500 
8s 200 250 250 200 250 500 200 
8t 200 100 500 100 250 500 200 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
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